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 Influenza A virus (IAV) is one of the most ubiquitous respiratory viruses in the world, 
causing significant disease burden in the United States and abroad.  Current vaccination 
strategies that target the generation of humoral immunity offer limited heterosubtypic protection; 
T cells offer cross-strain protection and the promise of universal immunity against IAV.  Local 
tissue immunity plays a key role in pathogen clearance and tissue protection, particularly in the 
form of tissue resident memory T cells (TRM), which are a non-circulating memory T cell subset 
that have been shown in a variety of tissue sites to be superior mediators of protection compared 
to circulating memory T cells.  At the same time, T cell immunity has been associated with 
inflammatory processes that may also lead to lung immunopathology.  How lung tissue localized 
T cell immunity mediates its protection during a recall response to IAV challenge is not well 
understood. 
 Using the lymphocyte sequestering drug FTY720, we show that primary infection with 
H3N2 IAV strain X31 provides tissue localized heterosubtypic immunity independently of 
humoral immunity against an H1N1 PR8 IAV strain.  Within the lung resident niche, the recall 
response drives faster CD4+ and CD8+ T cell expansion compared to a primary infection.  This 
rapid T cell expansion resulted from in situ TRM proliferation that was augmented by the 
migration of peripheral T cells.  By tracking a naïve T cell population specific for the IAV strain 
used in secondary challenge, we demonstrate that influenza-specific T cells, including those 
specific for newly introduced antigens, migrate to the lung niche from the local mediastinal 
 
 
lymph node (medLN) where both CD4+ and CD8+ T cells experience enhanced priming and 
proliferation.  We further show that primary infection fortifies the medLN with persistently 
increased numbers of T cells as well as both CD103+ and CD103- conventional dendritic cells 
(cDCs) that are transcriptionally similar to cDCs in an infection naïve mouse.  By depleting 
Zbtb46+ cDCs, we determine that cDC fortification is a crucial mechanism for enhanced T cell 
priming and expansion in the medLN during a recall response. 
 We also found that lung localized CD4+ T cell responses exhibit significant 
immunomodulatory function.  Polyclonal lung CD4+ TRM generated by influenza infection as 
well as lung OT-II TRM exhibit increased production of antiviral inflammatory cytokines in 
addition to enhanced IL-10 family cytokine production compared to splenic CD4+ effector 
memory T cells (TEM).  During a heterosubtypic challenge, we further observed that lung niche 
non-TRM CD4+ T cells produce significantly more in situ IL-10 compared to a primary 
infection, which modulated airway IFN-ɣ and TNF-α production without any depreciation in 
viral clearance.  Immunomodulatory characteristics of a recall response was reflected in lung 
tissue-wide transcriptional downregulation of innate responses such as type I IFN responses 
compared to a primary infection.  This work demonstrates the dual antiviral and 
immunomodulatory protective role of enhanced tissue-localized T cell responses during the 
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Chapter 1: Introduction 
1.1: Overview of influenza A virus infection 
 Influenza A virus (IAV) is an enveloped RNA virus of the family Orthomyxoviriade and 
can be either spherical or filamentous in shape, at sizes of approximately 100 nm in diameter or 
300 nm in length, respectively [1].  It is a tropic virus that infects humans who are exposed to 
droplets containing viral particle, typically in the upper respiratory tract, eventually spreading to 
the lower respiratory tract where it infects the epithelial cells of the airway and alveoli, inducing 
acute respiratory distress syndrome (ARDS) in the most severe clinical cases.  Although influenza 
virus consists of several subtypes, influenza epidemics are mainly caused by influenza A (>75%) 
[2].  
 The innate immune response immediately responds to IAV infection, producing a host of 
soluble antiviral mediators and triggering a tissue-wide antiviral state.  These include interferons 
(IFN-α, IFN-β, IFN-λ)  as well as pro-inflammatory cytokines (IFN-ɣ, TNF-α, IL-6, IL-1β) that 
may be produced by a wide variety of cells, including epithelial cells as well as specialized innate 
immune cells such as dendritic cells, macrophages, neutrophils, and natural killer cells [3].  Innate 
immune cells may kill infected cells, clear debris, or present viral antigen to T and B cells to 
activate the adaptive immune system, a function classically performed by dendritic cells. 
 Both CD4+ and CD8+ T cells mount a specialized and effective immune response that 
ultimately peaks several days after the initial viral exposure.  CD4+ and CD8+ perform essential 
roles in IAV clearance through robust cytokine and chemokine production as well as cytotoxic 
killing of virus-infected cells [4].  Activated B cells produce neutralizing immunoglobulins that 
clear virus and are critical to disease resolution and host recovery.   Upon resolution, long-lived 
plasma cells and memory T cells provide long-term adaptive immunity against the encountered 
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strain of IAV.  Here, we seek to better understand the mechanisms that contribute to T cell-
mediated immunity to IAV infection during a memory response.    
 
1.2: Influenza virus 
IAV is among the most prevalent infectious respiratory disease-causing viruses in the 
world, estimated by the Center of Disease Control to contribute to roughly 50,000 deaths and 
500,000 hospitalizations per year in the United States alone.   Epidemiologically, influenza is 
characterized by outbreaks in the northern and southern latitudes as the basic reproductive number 
(R0) increases during colder and drier winter months.  On the other hand, influenza prevalence 
tends to be more consistent in equatorial regions that have less seasonal climate variance.  The 
proliferation of international air travel has not only connected countries and people with one 
another, but also the diseases that they harbor, leading to a perpetual circulation of newly emerging 
strains of influenza.  New strains of influenza virus arise from minor genetic mutations of surface 
antigens known as antigenic drift, which allows the virus to elude immunity raised against prior 
iterations of the virus.  Although humans are a primary reservoir of pathogenic strains, influenza 
virus is widely circulated among many other animal species.  Strains of zoonotic origin contain 
particularly diverse and novel strains, most notably from wild avian reservoirs, which pass on to 
humans through domesticated poultry intermediates [5].  More dramatic alterations, known as 
antigenic shift, is typically caused by genomic reassortment between viral strains from different 
animal hosts.  Antigenic shift is associated with greater disease spread and severity due to 
significant immune evasion and contain increased pandemic risk; most recently, the pandemic 
2009 H1N1 strain emerged from a reassortment of human, avian, and swine flu genomic segments 
[6].   
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The viral structure consists of three major components: the viral envelope, matrix protein 
(M1), and its viral ribonucleocapsid (vRNP) core (Fig. 1.1).  The viral envelope is a phospholipid 
bilayer containing the major surface glycoproteins hemagglutinin (HA) and neuraminidase (NA), 
as well as the M2 ion channel (BM2 in influenza B), all of which play major roles in host cell entry 
and exit.  Surface glycoproteins NA and HA are the primary antigenic determinants of the adaptive 
immune response, and variations in these two proteins define the viral subtype.  The HA structure 
is composed of a cylindrical head, which is a trimeric, globular structure composed of three 
identical polypeptide chains that is connected to a stalk-like polypeptide stem.  HA comprises 
~80% of the viral envelope proteins and forms the spikes of the viral surface; HA mediates viral 
binding and fusion with the lipid membrane of target cells.  NA is a mushroom shaped tetrameric 
enzyme that is critical in catalyzing the release of sialic acid residues to facilitate both viral linkage 
and release.  Matrix protein M1 maintains and controls the structure of the viral particle.  The 
genomic core consists of eight distinct genomic RNA segments and its bound viral 
ribonucleocapsid (vRNP) core which consists of its trimeric RNA polymerase (PB1, PB2, and PA) 
and nucleoprotein (NP), which binds to RNA segments and facilitates full-length gene replication 
and transcription [7].    
At the cellular level, the IAV infectious cycle begins when viral HA binds to sialic acid 
residues on host cell glycoproteins and glycolipids, which initiates IAV internalization through 
receptor mediated endocytosis.  IAV sialic acid binding is highly specific and a determinant of 
species tropism. Because human respiratory epithelial cells mostly contain α(2, 6) linkages, IAV 
originating from different species such as birds, which are specific for α(2, 3) sialic acid residues, 
must mutate or acquire genetic material from other viruses in order to adapt to human sialic acid 
residues [8].  Upon endocytic fusion, the pH and K+ environment of the endosome lead to M2 
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channel activation and subsequent H+ influx and K+ efflux, leading to exit from the endosome. 
Newly released vRNP then enter the host cell nucleus and initiate transcription of positive sense 
RNA which is exported to the cytoplasm for protein translation.  Newly translated surface 
glycoproteins HA and NA localize and cluster at the assembly site, located on the apical side of 
the host epithelial cell membrane. Along with M1, these proteins alter the viral structure to initiate 
budding and further recruit M2 protein and vRNPs which are necessary for a complete viral 
particle [9, 10].  As the virus buds from the cell, NA cleaves the sialic acid – glycoprotein bonds 





Figure 1.1: Influenza A viral structure 
Influenza is a spherical or filamentous structure (spherical structure depicted) composed of a 
plasma membrane envelope that contains eight negative-sense RNA genomic segments.  
Nucleoprotein (NP) proteins are bound to the genomic segments which are read by RNA 
polymerases PA, PB1, and PB2.  M1 matrix protein maintains the structural integrity of the viral 
particle.  The M2 proton channel plays a key role in regulating viral pH to mediate viral component 
release after host cell entry.  Hemagglutinin (HA) and neuraminidase (NA) are the primary surface 
glycoproteins that recognize sialic acid residues and play key roles in host cell fusion and budding.  










1.3: Innate signaling responses to influenza A 
The innate immune response provides a multifactorial defense against pathogen infection 
that determine the outcome of disease progression.  The first line of defense are physical barriers 
such as the epithelial cell layer, which lines the respiratory tract and physically prevents pathogens 
from penetrating into the body.  At the physical barrier layer, epithelial and immune cells also 
secrete antimicrobial peptides including defensins and cathelicidins [11], whose mechanism of 
action is based upon their disruption of bacterial membranes.  Mucus production provides an 
additional barrier layer by preventing the attachment of the pathogen to the epithelium, and ciliary 
motion continuously clears mucus and trapped pathogen and debris.  However, because IAV 
directly infects epithelial cells, additional innate mechanisms are necessary for protection. 
Early IAV infection and proliferation triggers antiviral responses to enhance host cell viral 
resistance and inhibit viral replication.  Pathogen recognition receptors (PRRs) on host cells 
recognize pathogen associated molecular patterns (PAMPs), which are molecular motifs such as 
such as certain nucleic acids, protein structures, lipids, and carbohydrate structures that are unique 
for various pathogen classes (viruses, bacteria, fungi, and helminths).  The triggering of these 
receptors by influenza leads to the activation of many antiviral responses, including the secretion 
of cytokines and chemokines. 
The internalization of IAV and IAV-infected host cells introduces viral RNA that is sensed 
by Toll-like receptors (TLR) 3 and 7 in the endosome [12, 13] and retinoic acid-induced gene I-
like receptor (RIG-I) [14] in the cytoplasm, which comprise the two major sensor types that induce 
robust type I interferon (IFN) production [15, 16].  Type I interferons are produced by a wide range 
of immune and non-immune cells in the lung, including epithelial cells, dendritic cells, and 
macrophages.  Type I IFN bind to IFNAR and suppress viral replication by activating the 
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JAK/STAT pathway to upregulate interferon stimulated genes (ISG), which include hundreds of 
differentially expressed genes [17].  The orthomyxovirus resistance gene (MX) was one of the 
earliest discovered ISGs, and its lack of function in most laboratory mice strains are a key 
determinant for their susceptibility to influenza infection which demonstrates the importance of 
ISGs in anti-IAV immunity.  ISGs also inhibit viral replication through RNA cleavage [18], 
translational block [19], and viral cycle inhibition [20, 21] among many other mechanism.  While 
type I IFNs have broad effects on nearly all cell types, type III IFNs, specifically IFN-λ, perform 
similar functions but act specifically on epithelial cells including those in the respiratory tract [22].  
Influenza viruses evade the IFN system through their production of NS1, NEP, PB-F2, and PA-x 
to neutralize type I IFN signaling by suppressing downstream kinases and transcription factors 
[23], enabling a productive infection to take hold. 
Innate immune cytokines and chemokines also play a major role in protection by increasing 
inflammation and the recruitment of additional leukocytes.  Activation of the NLRP3 
inflammasome by macrophage and dendritic cell-derived IL-1 has been demonstrated to be 
essential for anti-IAV resistance [24, 25], although NLRP3 does not induce direct antiviral 
function.  TNF-α and IL-6 are further mediators of inflammation that are highly upregulated in 
bronchoalveolar lavage samples from patients [26] and are critical for antiviral protective effects 
[27, 28].  Chemoattractants are also produced at high levels to recruit immune cells as part of both 
the adaptive and innate responses.  IP-10, RANTES, and MCP-1 is secreted by epithelial cells to 
attract monocytes, DCs, macrophages, and effector T cells [29].  IL-8 production attracts 
neutrophils, while playing important roles in influenza protection and recovery.  However, while 
inflammatory cytokines and chemokines are essential for antiviral protection, increased production 




1.4: Innate cellular response to influenza 
The innate immune response to IAV is not confined to soluble mediators; neutrophils, 
macrophages, dendritic cells, and NK cells play diverse roles in early antiviral immunity such as 
environmental surveillance, cytokine production, cytolytic effector activity, debris clearance, 
tissue repair, and antigen presentation (Fig. 1.2).  Early in the course of infection, natural killer 
(NK) cells kill infected host cells early in the course of infection prior to the development of 
adaptive immunity.   NK cells utilize a combination of perforin and granzyme release, Fas 
mediated apoptosis, and antibody-dependent cellular cytotoxicity (ADCC) to kill infected cells.  
Defective NK function leads to impaired viral clearance and increased morbidity and mortality in 
mouse models [31]. PMNs, also known as neutrophils, are the most abundant leukocyte in the 
blood and rapidly respond to bacterial threats through mechanisms such as phagocytosis and 
release of anti-bacterial enzymes [32].  Though excess neutrophilia is associated with increased 
morbidity, neutrophil function remains crucial for both protection and resolution of influenza 
infection [27, 33]  Dendritic cells (DCs) and macrophages also play critical effector and 
maintenance roles and are the primary professional antigen-presenting cells (APCs) in the IAV 
response, representing a bridge to adaptive immunity.  
 
Macrophages 
Macrophages are primarily phagocytic cells which engulf bacteria and cellular debris upon 
PRR stimulation. Macrophages are present in virtually all tissue sites and are important not only 
for host defense but also tissue maintenance and equilibrium, particularly in anti-inflammatory and 
tissue repair functions [34-36].  In the lung, two major macrophage populations are present: 
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alveolar macrophages (AM) and interstitial macrophages (IM).  IM express high levels of CD11b 
expression and low levels of CD11c.  IM are found in the lung parenchyma and are thought to play 
an immunomodulatory role because of their high IL-10 production [37, 38].  Located within the 
airway lumen, AMs can be identified by high surface expression of CD11c and Siglec-F as well 
as low expression of CD11b.  Of the two lung macrophage populations, AM have been found to 
be most critical for host defense due to their highly phagocytic nature and secretion of 
inflammatory, anti-pathogen factors such as nitric oxide (NO), IFN-ɣ, TNF-α, and IL-6.  
Furthermore, AM have also been shown to reduce inflammation and repair damaged tissue through 
phagocytosis of apoptotic cells in a process known as efferocytosis its byproduct prostaglandins 
[39].  Aberrant AM phagocytosis has been implicated in human disease such as asthma [40, 41], 
chronic obstructive pulmonary disease [42], and interstitial lung disease [43].    
 
Dendritic Cells 
Dendritic cells are a cornerstone of innate immunity, performing early innate effector 
function as well as antigen presentation to activate the adaptive immune response.  Dendritic cells 
are critical immune sentinels and highly responsive to environmental cues.  DC patrol and sample 
the local milieu for antigen to present and prime T cells, bridging the innate and adaptive immune 
responses.  DCs are among the earliest responders to influenza and are represented by a 
heterogeneous population that includes conventional DCs (cDCs), monocyte-derived DCs 
(moDCs), and plasmacytoid DCs (pDCs).  Though these subtypes all derive from common bone 
marrow progenitors [44], their lineages (Fig. 1.3) and function have distinct differences.   
Plasmacytoid dendritic cells are functionally distinct from other DC subsets, offering little 
in the way of antigen presentation but playing an outsized role in early interferon and cytokine 
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production.  They are characterized by their antiviral function and low expression of CD11c, 
myeloid markers, and MHC class II, which corresponds with less efficient antigen presentation 
[45].  pDCs express very high levels of TLR7 and TLR9 [46] and rapidly produce antiviral 
cytokines such IFN-α in the presence of viral nucleic acids [47, 48].  Upon exposure to IAV, pDCs 
rapidly release large quantities of type I IFN and other cytokines, playing a major role in early 
antiviral immunity (Fig. 1.2). Impaired pDC activity has been linked to significantly impaired 
antiviral function [49].  However, pDCs have also been shown to be dispensable in a sublethal 
IAV infection [50], suggesting that their contributions to anti-IAV immunity are not well defined. 
Monocyte-derived DCs derive from blood-borne monocytes and are phenotypically similar 
to cDCs due to their efficient antigen presentation capabilities and high CD11c expression, but are 
distinct in lineage and lack cDC markers FLT3 and ZBTB46.   IAV-induced inflammation recruits 
monocytes to the lung tissue as well as draining lymph nodes where they differentiate into moDCs.  
However, their role in mediating protective immunity is unclear as IAV-induced lymph node 
moDC have poor T cell priming function [51]. 
Conventional DCs are superior antigen presenters compared to other DC subsets and 
exhibit the ability to cross-present antigen on MHC class I.  Respiratory cDCs are primarily 
comprised of CD11b- CD103+ and CD11b+ CD103- subsets which  localize to the airway mucosa 
and the lung parenchyma, respectively [52].  These cDCs continuously sample their environment 
through constitutive macropinocytosis [53].  After exposure to IAV, lung and airway DCs acquire 
IAV antigen through a combination of receptor-mediated endocytosis of viral particles as well as 
phagocytosis of host infected cells (Figure 1.2) [54, 55].  cDCs may also acquire antigen by 
becoming infected themselves; in vitro studies show that cDCs may be infected by IAV [56, 57], 
although animal studies have suggested that DC infection is not a necessary requirement for 
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antigen acquisition and transport.   Upon transport to the lymph nodes, migratory DC transfer 
antigen to lymph node DC as well, providing a mechanism for the efficient distribution of IAV 
antigen to all LN DC and increasing the number of APCs that can activate the anti-IAV T cell 
response [58]. 
IAV infection also produces inflammatory signals (e.g. PRR activation, cytokine signaling) 
and activates cDCs which then undergo rapid maturation which manifests in increased expression 
of co-stimulatory molecules such as CD80 and CD86 as well as homing receptors such as CCR7 
[59].  Upon antigen acquisition, the CD11b-CD103+ subset, also known as the migratory subset, 
more rapidly and efficiently migrates to the draining mediastinal lymph node (medLN) [60].  
Ultimately, both CD11b+ and CD103+ respiratory cDCs subsets eventually migrate to the medLN 
along the CCL21 gradient to the afferent lymphatic vessels of local lymph nodes [61].  An intra-
nodal CCL21 gradient further directs activated cDCs into the T cell rich zone where they can 
effectively initiate the adaptive immune response [62].  Conventional DCs have been shown to be 
essential to T cell responses and the depletion of CD11c+ DCs during IAV infection significantly 
impairs viral clearance and clinical severity in a murine model [51, 63].  Although innate and 





Figure 1.2: Innate cellular responses to influenza A 
A constellation of innate cells rapidly responds to IAV infection.  Plasmacytoid dendritic cells 
(pDC) rapidly produce large quantities of type I interferons to promote tissue-wide antiviral 
function.  Natural killer cells (NK) kill infected host cells through both the release of soluble 
mediators and receptor-ligand mediated cell death.  Alveolar macrophages (AM) and 
polymorphonuclear cells (PMN) phagocytose cellular debris to maintain tissue homeostasis and 
produce cytokines that amplify the immune response.  Interstitial macrophages (IM) are present 
in lower levels but also produce cytokines.  Conventional and monocyte-derived dendritic cells 
(DC) acquire viral antigen through host cell phagocytosis and receptor-mediated endocytosis of 








Figure 1.3: DC lineage development 
All dendritic cell subsets derive from monocyte-dendritic cell progenitors (MDP) which ultimately 
derive from hematopoietic stem cells (HSC) in the bone marrow.  These MDPs may yield 
monocytes or common dendritic precursors (CDP).  Monocytes exit the bone marrow to circulate 
throughout the body and under certain conditions, may differentiate into monocyte-derived 
dendritic cells (moDC) at the tissue site.  In the bone marrow, CDPs may differentiate into 
plasmacytoid dendritic cells, which circulate throughout the body, or into pre-dendritic cells (pre-
DC), which also circulate throughout the body.  Conventional dendritic cells may then derive from 










1.5: Adaptive response to primary IAV infection 
Humoral immunity 
The adaptive immune response is essential to mounting protective immunity to influenza 
infection.  Early animal studies demonstrated that recovered animals developed transferrable, 
efficacious humoral immunity [64], and antibody titers remain the gold standard to test influenza 
immunity today. Antibodies target the surface of the IAV particle and so antibody specifies are 
dominated by the major surface glycoproteins HA and NA though minor levels of antibodies can 
be detected against NP and matrix proteins.  During exposure to IAV strains, humoral immunity 
protects the host to varying degrees based upon prior exposures by infection or vaccination [65].  
In the absence of complete protection, naïve B cells are activated by viral antigen and CD4 help, 
differentiating into plasmablasts to produce low affinity decavalent IgM which peaks about a week 
after initial infection and provides a low level of humoral protection during the course of infection 
[66].  Bivalent, high affinity IgG antibodies are not produced until weeks after initial infection, but 
are critical to complete viral clearance and maintaining long-term immunity.  B-cell deficient mice 
exhibit significantly greater susceptibility to and poorer recovery from primary IAV infection 
compared to B-cell competent mice [67].  Upon the resolution of infection, long-lived plasma cells 
continue to produce IgG that provides lifelong protection. 
Cellular immunity 
T cell immunity is another branch of adaptive immunity that can confer broad, cross-strain 
protection against influenza.  In addition to HA and NA, a significant proportion of CD4+ and 
CD8+ T cell epitopes are also derived from proteins NP and M1; CD8+ T cell epitopes have been 
found that derive virtually every influenza protein [68].  This broader antigenic response provides 
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T cell responses against highly conserved, internal proteins that enable efficacious cross-strain 
immunity that is not possible for humoral immunity. 
Naïve T cells continuously circulate between lymphoid organs, entering lymph nodes (LN) 
from the blood, and spend about 8-12 hours within the LN cortex, probing for their cognate antigen 
[69].  Like activated DCs which migrate to LNs, naïve T cells express high levels of CCR7 that 
guide their migration from lymphatic and blood to the LN where CCL19 and CCL21 are expressed 
in the high endothelial venules and especially the T cell cortex [70].  In order to exit the lymph 
node, naïve T cells follow a sphingosine 1-phosphate (S1P) gradient that is elevated in the blood 
and lymph.  S1P is produced in nearly all tissues, and its gradient is generated by S1P lyase which 
degrades S1P in the peripheral tissue [71].  Activated T cells temporarily upregulate the marker 
CD69 which blocks the S1P signaling pathway by suppressing S1P receptor function which arrests 
migration of newly activated T cells [72].  This mechanism blocks the egress of newly actively T 
cells which allows them to remain with their cognate antigen as the T cell response develops.  S1P 
blockade has been shown to prevent the LN egress of lymphocytes based upon experiments using 
the drug FTY720 [73], although its efficacy during an active IAV infection is less clear. 
The T cell activation process is comprised of 3 distinct “signals” that dictate the outcome.  
The first signal is the TCR engagement with the cognate antigen peptide-MHC complex, known 
as the immunological synapse.  In addition to a sustained TCR signal, studies determined that T 
cells activated without a costimulatory second signal were rendered anergic, unable to respond to 
future TCR signaling [74].  Classically, CD28 is the major costimulatory protein on T cells that 
engages with CD80 and CD86 (B7.1/B7.2) on the surface of APCs by reducing the number of 
TCRs required in the SMAC [75], lowering the activation threshold and activating downstream 
pathways that promote T cell proliferation and survival [76].  Finally, T cell activation requires a 
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third cytokine signal that is typically provided by antigen presenting cells and the priming 
environment.  T cells that do not receive this signal fail to develop effector function.  APC cytokine 
production is dependent on the infectious agent and may include the production of general 
inflammatory signals or even more immunomodulatory signals [77], suggesting that dendritic cells 
prime T cells to generate the optimal subtype of effector T cells necessary to resolve the original 
stimulus.   
Effector T cells consist of several functionally distinct, non-overlapping subsets that are 
specialized to combat different pathogen classes.  While CD8+ T cells generally differentiate into 
cytotoxic T cells (CTLs), CD4+ T cells exhibit significant plasticity and may differentiate into Th1, 
Th2, Th17, and T regulatory cells (Treg), among other subsets.  Th1 cells are characterized by 
their cytokine effector function, producing IFN-ɣ and TNF-α that is critical for antiviral immunity.  
On the other hand, Th2 cells mediate immunoglobulin production as well as allergic and 
antiparasitic function.  Th17 cells are involved in inflammatory process and often associated with 
autoimmunity, while Treg produce IL-10 and TGF-β and have strong immunosuppressive 
function. 
During IAV infection, DC production of IL-12 during T cell priming induces Type 1 
polarization to produce high numbers of CTLs as well as Th1 CD4+ T cells in the lung draining 
lymph nodes where effector T cells downregulate CCR7 and upregulate CXCR3 and CCR4, 
mediating their migration to IAV-infected lung [78].  Effector CD4+ cells and CTLs that migrate 
to the lung and airways produce a broad range of cytolytic compounds (granzyme B, perforin) and 
cytokines (IFN-g, TNF-a, IL-2) that are critical to IAV clearance.  Secreted IFN-ɣ is the most 
prominently produced antiviral cytokine and leads to tissue-wide upregulated interferon signaling.  
TNF-α, also robustly secreted, leads to broad proinflammatory responses which triggers greater 
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cell death amplifies inflammatory and chemokine signaling that enhance antiviral responses but 
may also mediate tissue damage as well [79].  T cells also coordinate the greater immune response 
by producing the chemokine macrophage inflammatory protein (CCL3) which recruits monocytes, 
lymphocytes, DCs, and neutrophils to clear IAV from the site of infection [80].  CD4+ T cell-
mediated protection is abrogated in the absence of B cells and CD8+ T cells [81], suggesting, that 
coordination with other immune cells is essential for CD4+ protective function.  CD4+ T cells also 
offer more diverse function, differentiating into T follicular helper cells that are critical to the 
formation of germinal centers and immunoglobulin class switching that produces neutralizing IgG 
[82].  Additionally, the loss of CD4+ or CD8+ T cell responses led to impaired viral clearance and 
increased mortality, although the presence of other immune cells is sufficient for protection in less 
virulent challenges. [83, 84], In addition to pro-inflammatory mediators, both CD4+ and CD8+ 
effector T cells have also been shown to produce IL-10 in IAV mouse models, suggesting that T 






Figure 1.4 T cell priming 
Naïve T cells are primed in secondary lymphoid sites by conventional dendritic cells that present 
peptide on major histocompatibility complex (MHC).  Naïve T cells require 3 signals in order to 
properly differentiate into effector T cells.  (1) Naïve T cells which possess the TCR specific for 
the presented peptide will receive signal 1 which is dependent on TCR engagement.  (2) Activated 
dendritic cells contain costimulatory molecules such as CD80 and CD86 which engage with CD28 
on the T cell in order to provide signal 2.  (3) Finally, dendritic cells produce cytokines that provide 













1.6: Memory T cells  
Memory T cells are a heterogenous subset of T cells that are distinct from naïve T cells due 
to their ability to respond more rapidly and effectively upon antigen exposure.  The precise 
mechanisms of memory T cell generation are not fully understood, as to memory T cells may also 
develop memory-like characteristics in the absence of foreign antigen [86].  Canonically, memory 
T cells are generated after a primary exposure from the expanded effector T cell pool which 
contains memory T cell precursors.  After pathogen clearance, the effector T cell pool contracts to 
leave behind a small, long-lived subset that persists as so-called “memory” for their ability to 
remember the primary infection by rapidly responding to the same pathogen. 
Heterogeneity of memory T cell migration patterns are a major determining factor in their 
functional characteristics. Studies in blood identified circulating populations memory T cells that 
migrate between either peripheral tissue or secondary lymphoid organs.  Central memory T cells 
(TCM) are a circulating subset of memory T cells which localize to secondary lymphoid sites 
including lymph nodes as well as the spleen.  TCM are identified by surface markers that define 
both their memory status as well as their migratory characteristics.  In humans, these cells can be 
defined by the upregulation of chemokine receptor CCR7, and in mice, the upregulation of CD62L, 
surface proteins that facilitate their localization to lymphoid sites.  Mouse models have 
demonstrated that TCM exhibit functional differences including enhanced IL-2 production and 
cellular proliferation after T cell antigen stimulation which augments lymphoid T cell responses 
[87].  Effector memory T cells (TEM) comprise the other major subset of circulating memory T 
cells and migrate between peripheral tissues and the blood.  Unlike TCM, TEM at steady state are 
characterized by low expression of CCR7 in humans and low expression of CD62L in mice, which 
facilitates their migration to peripheral tissue rather than lymphoid sites.  TEM possess enhanced 
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cytolytic function and effector cytokine production [88], which corresponds to their localization 
in peripheral tissue sites, which are most likely to be sites of pathogen exposure.   
 
Tissue resident memory T cells 
In addition to the TEM and TCM memory T cell subsets, another subset known as tissue 
resident memory T cells (TRM) has become more recently appreciated for its role in protection 
and rapid response.  In contrast to TEM and TCM which circulate between the blood and peripheral 
tissue or secondary lymphoid organs (SLO), respectively, TRM are a memory T cell population 
that resides in tissues without recirculating throughout the body (Fig. 1.5) [89, 90].  Parabiosis 
experiments in mice have functionally demonstrated that TRM are non-circulating [91].  TRM 
comprise the largest subset of memory T cells in the body, residing in a wide range of tissues such 
as barrier sites like the lung, skin, and gut, and female reproductive tract (FRT), lymphoid sites, 
and other non-lymphoid tissue such as the brain, liver, and kidneys [92-100].  As they tend to 
persist within peripheral tissue sites, TRM also share phenotype characteristics with TEM, 
upregulating CD44 and downregulating CD62L in mouse models and downregulating both 
CD45RA- and CCR7 in humans.   TRM exhibit transcriptional signatures distinct from circulating 
memory T cells [101, 102], and murine TRM as a collective group share a common transcriptional 
core mediated by the transcriptional factors Hobit and Blimp1 [97].  A number of approaches such 
as intravascular labeling [103, 104], parabiosis [91], and tissue transplantation [105] have shown 
that TRM permanently reside within tissue niches without recirculating into the blood or lymph 
and are associated with surface proteins such as CD69, CD103, and CXCR6 which mediate tissue 
retention and migration.  However, such markers are not always expressed by TRM nor are they 
wholly unique to TRM as well.  Therefore, tissue residency is functionally defined by a lack of 
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migration to the blood and other tissue sites [91, 106].  Therefore, the term TRM describes a 
collective, heterogenous group of tissue-retentive, non-circulating memory T cells with distinct 
functional characteristics. 
The mechanisms driving lung TRM generation and maintenance have not been fully 
elucidated.  Local infection is a key driver of TRM generation, but the relative contributions of 
generalized inflammation and in situ antigen recognition are unclear.   Recent work has found that 
T cells may can be conditioned for a TRM fate by cytokine signaling during the priming step [107, 
108].  In the lung, the persistence of antigen may be critical to maintaining TRM upregulation of 
chemokine receptors has been shown to regulate TRM localization to airways [109].  At steady 
state, evidence suggests that lung TRM are replenished from T cells within the lung interstitium 
rather than being replenished from sources outside of the resident niche [110].  Lung TRM 
generated by IAV infection have been known to decline in number over time unlike other tissue 
TRM which experience longer persistence, and this diminishment is associated with declining 
protection as well [111].  This may be partially explained by the fact that lung TRM, and especially 
airway TRM, are limited in their access to blood borne nutrients and experience amino acid 
starvation, promoting cell death and contributing to the long-term loss of TRM numbers [112].  By 
repeated pathogen exposure, TRM numbers and durability can be boosted [113], suggesting that 
lung TRM persistence may depend on the continually environmental exposure experienced under 
normal physiologic conditions.   
While CD4+ and CD8+ TRM share many similarities, including a core transcriptional 
signature [101], several key differences exist in their functional capacity and roles.  CD4+ TRM 
represent a more heterogenous population in clonal diversity, likely reflective of the functional 
plasticity and heterogeneity of CD4+ T cells, which can differentiate into many helper T cell 
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subsets.  In addition to Th1 polarized TRM, Th2 and Th17 polarized TRM have also been 
discovered to play roles in allergic immunity in a house dust mite model [114] as well as 
antibacterial function in a Klebsiella pneumonia model of infection [115].  As such, CD4+ TRM 
can produce a diverse range of Th1, Th2, and Th17 cytokines, whereas CD8+ TRM tend to 
primarily produce cytotoxic mediators as well as Th1 cytokines such as IFN-ɣ and TNF-α 
cytokines. CD4+ and CD8+ have also been shown to occupy different tissue niches that optimize 
their differing function. CD8+ TRM tend to localize within the epithelial layers of tissue sites 
which optimizes their rapid cytotoxic function, whereas CD4+ TRM tend to localize in clusters 
[116] below the epithelial layer where they are better position to provide supporting cytokine 
production to coordinate the immune response and interact with APCs [117].  Both CD4+ and 






Figure 1.5 Memory T cell migratory characteristics 
T cells subsets are defined by their migratory characteristics.  Naïve T cells migrate in the blood 
and lymph to various lymphoid sites until cognate antigen encounter.  Effector (TEM) and 
central (TCM) memory T cell subsets are migratory memory T cells that can be found in the 
blood.  TCM primarily localize to secondary lymphoid sites whereas TEM migrate to peripheral 
tissue.  Tissue resident memory T cells (TRM) are a non-migratory subset that resides primarily 







1.7: Tissue resident memory T cell antiviral protective capacity 
TRM localized patrol function  
TRM mediate protection in several viral infection models including not limited to, 
influenza [94, 100, 118, 119], HSV [116, 120, 121], vaccinia [122, 123], and LCMV [124] and 
provide superior protection compared to circulating memory T cells.  Located at the site of 
infection, TRM patrol the tissue milieu to respond to invading pathogens with rapid cytolytic and 
cytokine function.   
TRM at steady state are relatively fixed within their niche and do not migrate to other 
locations within the tissue [125].  However, despite their restrictive localization, TRM are hardly 
sessile.  Significant evidence has shown that at steady state, TRM demonstrate motile features 
within their tissue site as a part of their sentinel function (Fig. 1.6).  Intravital imaging showed that 
murine skin CD8+ TRM slowly (~1-2 µM/min), but efficiently crawl within the epidermis in order 
to expand their patrol function and exhibited dendritic features while scanning for antigen [126, 
127].  Upon antigen stimulation, skin CD8+ TRM retract their dendritic extremities and arrest their 
motility, lending credence to the hypothesis that TRM motility supports a sentinel role that is 
fulfilled upon pathogen encounter.  Using an ex vivo fluorescent labeling and culture system with 
human skin biopsies, recent imaging studies corroborated past animal studies and showed that 
human CD8+ TRM actively migrate within both dermal and epidermal skin layers and arrest upon 
antigen exposure [128].  Another recent study showed that CD8+ TRM do not preferentially 
migrate toward infected cells, suggesting that TRM cellular density may be crucial toward 
increasing the odds of a chance encounter [129] 
TRM motility is highly tissue dependent, where differences in architecture may account 
for discrepancies in local TRM migratory patterns.  Hepatic CD8+ TRM which reside within 
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sinusoids showed track speeds ~5 µM/min, several times faster than epidermal TRM [96].   Unlike 
skin TRM, FRT TRM exhibited relatively high speeds of ~10 µM/min within the FRT stroma and 
motility remained high after viral clearance [130].  FRT TRM speeds were dependent on the type 
of uterine connective tissue layer, in which collagen-dense regions were correlated with slower 
speeds compared to collage poor areas.  CD8+ TRM in the small intestine also exhibited motility 
that varied depending on which tissue layer of the small intestine they were located [131], further 
suggesting that architectural constraints of the tissue are a key determinant of TRM motility.   
TRM are also thought to permanently reside within their tissue site without migration into 
blood or lymph, offering local protection against future pathogen exposures.  Challenging this 
dogma, recent work revealed that activated TRM exhibit developmental plasticity and re-enter the 
circulating pool by differentiating into central and effector memory T cells (Fig. 2) [132].  
Furthermore, these differentiated circulating memory T cells retain their TRM origins and are able 
to re-differentiate back into TRM upon appropriate cytokine stimulation.   These findings offer 
new mechanisms for TRM generation and protection, in which TRM may supply a bloodborne 
reservoir for the influx of effector and memory T cells to the site of infection as well.  Recent 
corroborating work in human samples discovered the presence of CD4+ CD103+ TRM cells in 
blood that were both functionally and transcriptionally similar to CD4+ CD103+ TRM in the skin 
[133].  Using a human skin xenograft model in mice, the authors determined that CD4+ CD103+ 
cutaneous TRM were able to reseed distal skin sites without needing to differentiate into a 
circulating memory subset unlike the previous murine study.  These results demonstrate an 
additional mechanism of protection that allows for seeding of distal, pathogen naïve tissue sites by 
differentiation into circulating memory subsets.  TRM entry into circulation may also underly 
findings from a recent study in which lung donor recipients experienced greater clinical 
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complications when donor lung TRM numbers diminished in the tissue site [106].  However, it is 
unclear whether TRM in other than the skin sites also exhibit the same migratory capabilities, as 
the vast majority of TRM remain restricted within their tissue site.   
 
Rapid TRM effector response 
Situated at the site of infection, TRM are poised to rapidly respond to pathogens through 
the release of cytotoxic and inflammatory compounds which are essential to CD8+ TRM mediated 
protection (Fig. 2).  Enhanced cytolytic function underlies their superior protective capacity.  CD8+ 
TRM have been shown in various murine models to constitutively express enhanced levels of 
cytotoxic proteins granzyme B and perforin [124, 134-136].  TRM cytolytic activity may also be 
dependent on anatomical location: CD8+ airway TRM offered little cytolytic activity in contrast to 
their parenchymal counterparts in the lung [119].  Yet, studies in human TRM have not necessarily 
recapitulated these same results in mouse models; TRM isolated from post-mortem human brain 
and lung express minimal protein levels of perforin or granzyme B [137-140].  Inhibitory proteins 
including PD-1, CTLA-4, and Tim-3 are highly expressed in TRM, suggesting that expression of 
cytolytic proteins may be purposefully low as part of an overarching immunoregulatory program 
to minimize TRM-mediated tissue damage. CD4
+ and CD8+ TRM have also been found to 
upregulate inhibitory proteins such as PD-1 in various other tissues including the spleen, pancreas, 
and skin, [95, 101, 141], suggesting that immunoregulation may be a universal hallmark of TRM 
and associated with their long-term persistence in tissue sites.  A recent study highlights the 
pathologic potential of TRM, demonstrating in an aspergillus model that that lung CD103lo CD69+ 
CD4+ TRM cause lung inflammation and fibrosis [142].  While human TRM may express low 
protein levels of cytotoxic mediators at baseline, granzyme and perforin mRNA are highly 
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expressed, are rapidly produced upon stimulation.  These studies have found that TRM are poised 
to quickly abandon their immunoregulated state to rapidly upregulate cytolytic activity upon 
antigenic stimulation or type I IFN signaling within the tissue milieu [138, 139, 143]. 
TRM produce robust levels of Th1 cytokines and chemokines in order broadly enhance 
tissue-wide antiviral responses and mediate leukocyte recruitment which are critical for protection 
and viral clearance (Fig. 2) [118, 119, 144, 145]. At rest, both CD4+ and CD8+ TRM exhibit 
elevated levels of preformed IFN-ɣ transcript that aids in the immediate and robust IFN-ɣ 
production upon restimulation [101, 138, 139].  Recent work on lung CD4+ CD103+ TRM found 
that Actinomycin D treatment, which blocks de novo transcription, dramatically reduced IFN-ɣ 
production which indicates that much of superior TRM cytokine production was due to enhanced 
transcription, suggesting that TRM may perhaps contain a more accessible IFN-ɣ locus [143].  
Recent work on CD8+ TRM in human skin found that CD49a+ identifies IFN-ɣ producers whereas 
CD49a- TRM produced IL-17A [146].  CD49a+ TRM preferentially localize to the epithelial layer, 
where enhanced effector function is best suited.  Within several hours of stimulation with cognate 
antigen, TRM produce IFN-ɣ which induces a tissue-wide antiviral state that is reflected by broad 
transcriptional changes, including the upregulation of type I IFN signaling and chemokine genes 
[125].  Murine studies in an FRT model found that IFN-ɣ produced by TRM created a state of alert 
in the tissue that activated natural killer cells and dendritic cells and directed the recruitment of 
not only effector T cells, but also unstimulated memory T cells and B cells to the site of infection 
via chemokine release and the upregulation of adhesion molecules on vascular endothelium [144, 
147].  early protective responses by activating the antiviral innate responses response and initiating 




In situ TRM proliferation 
In addition to leukocyte recruitment, TRM proliferation also contributes to the expanding 
immune effector pool in the tissue niche (Fig. 2) [129, 130, 148].  In the skin and FRT, recent 
studies demonstrated that TRM proliferated within the tissue niches to produce additional TRM 
that continue to reside within the original tissue site [129, 130, 149].  This proliferation dominates 
cellular expansion during the early recall response to both pathogen and peptide challenge.  Using 
parabiotic mice, cellular expansion was dominated by host cell responses, indicating that 
circulating T cells were not significant contributors [130].  Non-specific bystander T cells from 
the circulation also contributed to the generation of de novo TRM, suggesting that the initiation 
and maintenance of a TRM program is not dependent on cognate antigen recognition.  Newly 
generated TRM did not displace existing TRM, supporting recent studies which demonstrate that 
TRM numbers can be continually increased with repeated pathogen or antigen exposures [113, 
150, 151].  In situ TRM proliferation may also provide an expanded T cell pool that migrates to 
distal infection sites.  While proliferating TRM can differentiate into circulating memory cells that 
may migrate to tissue sites [132], recent work using a heterosubtypic influenza infection model 
determined that lymphoid TRM rapidly proliferated within the lung draining mediastinal lymph 
node which coincided with rapid expansion of lung effector T cells [152].  On the other hand, a 
recent study of skin TRM in a peptide challenge model did not find evidence to support in situ TRM 
proliferation as the dominant source of TRM expansion [150].  CD8+ TRM expansion after peptide 
stimulation was eliminated with systemic anti-CD8 antibody treatment, suggesting that circulating 





Figure 1.6: TRM protective antiviral function  
TRM mediate their protective antiviral function through a variety of mechanisms. TRM patrol 
their respective tissue niches and arrest their motility upon pathogen encounter.  In order to control 
viral infection, TRM rapidly produce cytotoxic mediators such as granzyme B and perforin as well 
as effector cytokines such as IFN-ɣ, which induces a tissue wide antiviral state.  TRM may also 
proliferate in situ in order to magnify their protective response.  TRM-induced chemokine 
production mediates rapid leukocyte recruitment including memory T cells and B cells.  TRM may 
also differentiate into circulating TEM and TCM memory subsets and migrate, providing a 







1.8: Trained innate immunity 
Though immunological memory is largely thought to be the purview of the adaptive 
immune system, recent evidence suggests that innate immune cells also have the capacity to 
optimize their responses against subsequent pathogen exposures, in a phenomenon known as 
trained immunity.  While adaptive immunity is thought to provide lifelong protection, trained 
immunity tends to reversible, persisting only on the order of months to years [153].  Even in the 
absence of T and B lymphocytes, RAG1 mice are protected against subsequent re-exposure to C. 
albicans; primary infection epigenetically reprogrammed monocytes to enhanced further cytokine 
production [154]. Prior respiratory viral exposure has also been shown to induce long-lived 
memory alveolar macrophages which coordinate neutrophil responses to S. pneumoniae challenge 
in a cytokine and chemokine dependent fashion, suggesting that innate immune immunity may 
provide protection against an incredibly broad range of pathogens [155].  It has been observed that 
vaccinations in humans may also provide non-specific protective benefits such as in the case of 
BCG, measles, and oral polio vaccine, in which the reduction in overall mortality cannot solely be 
attributed to elimination of those specific pathogens [156] and include concurrent enhancement of 
T cell immunity [157]. 
Though the underlying mechanisms of trained immunity remain to be fully elucidated, it 
is clear that epigenetic reprogramming underlies many instances of innate memory.  Myeloid cell 
stimulation durably increases the acetylation and RNA polymerase recruitment at inflammatory 
gene loci, long after the resolution of inflammatory stimuli [158].  Trained immunity also derives 
from changes to cellular metabolism that modulate epigenetic profiles [159]. Activation of the 
mTOR/Akt pathway by β-glucan from C. albicans was shown in human monocytes and mouse 
models to underly trained monocyte immunity [160].  These immunological changes are not 
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limited to protective responses, but can also induce tolerization as well [161].  The long-term 
effects of primary pathogen exposure on innate cells cannot be discounted when considering the 
ramifications of immunological memory. 
 
1.9: Thesis Aims 
Aim 1: Assess the lung localized antiviral T cell responses that contribute to heterosubtypic 
protection during an influenza infection 
 T cell-mediated immune responses offer the promise of universal protection against 
influenza A virus.  Much evidence has emerged that tissue-localized T cell responses provide 
optimal protection against a host of viral pathogens, particularly in the form of  TRM, which have 
been shown in several murine models to provide heterosubtypic immunity against IAV [94].  
However, tissue resident memory T cells are not the only driver of local tissue memory responses; 
circulating memory T cells as well as innate cells also contribute to protective immunity.  How 
these different aspects of T cell responses coordinate to mediate lung localized cross-strain 
protection against influenza has not yet been fully elucidated.  Our objective is to determine the 
difference between a recall and primary infection’s lung tissue localized T cell responses that 
contribute to protective immunity and investigate those underlying mechanisms.   
 Here we demonstrate that prior IAV infection generates tissue localized immunity that 
protects against heterosubtypic influenza challenge in a B cell independent manner.  By 
sequestering blood lymphocytes with the drug FTY720, we investigated tissue-localized immunity 
and discovered that compared to a primary infection, the recall response initiates a more rapid 
expansion of lung niche T cells that partially results from in situ proliferation CD4+ and CD8+ 
TRM, consistent with recent studies of TRM in other tissue sites [129, 130].  But unlike other 
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tissue sites, we also observed significant proliferation of non-TRM in the lung niche.  By tracking 
an influenza specific, naïve T cell population, we demonstrated that peripheral T cells migrate into 
the lung niche to contribute to the rapid T cell proliferation during a recall response.  Further, this 
migration was antigen-specific rather than being due to non-specific inflammation and 
chemoattraction.   
Increased lung T cell migration resulted from enhanced priming and proliferation within 
the lung-localized medLN.  During a recall response, we found that both naïve CD4+ and CD8+ T 
cells experienced more rapid priming and enhanced proliferation within the medLN, leading to 
enhanced migration of T cells to the lung niche, including T cells specific for novel antigen.  
Underlying this enhancement were persistent changes to the medLN, which led to increased 
numbers of T cells and cDCs that persisted for at least several weeks after a primary IAV infection.  
Through the depletion of Zbtb46+ cDCs, we find that the increased number of dendritic cells are 
key drivers of the enhanced T cell priming phenomenon observed in the recall response.  Together, 
these data suggest that a primary influenza infection leads to durable changes in innate immunity, 
specifically in dendritic cell numbers that enhance the adaptive T cell response, including T cell 
responses to novel antigen, which are necessary for heterosubtypic immunity.    
 
Aim 2: Assess immunomodulatory responses of the recall response to influenza viral challenge  
 Although a robust immune response to respiratory infection is paramount to viral clearance 
and a return to tissue homeostasis, associated inflammatory processes represent an altogether 
separate threat to tissue integrity and host health.  The virulence of a given influenza strain is 
highly correlated with the hyperinduction of proinflammatory cytokine production, also known as 
a cytokine storm [162].  Immunomodulatory cytokines are produced by a variety of immune cells, 
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including T cells, in order to dampen inflammatory responses.  During an influenza infection, T 
cells, including both effector and Treg cells, have been demonstrated to be major producers of anti-
inflammatory cytokines.  However, the role of anti-inflammatory T cell responses during a 
memory response have not been well studied.  Our second objective is to assess the 
contributions of T cells to the immunomodulatory function of the lung localized immune 
response during a recall infection  
 Our work found that in vitro stimulation of tissue resident memory T cells led to the 
superior production of both immunomodulatory IL-10 family and pro-inflammatory cytokines 
compared to their circulating counterparts.  Further, lung-derived APCs promoted T cell 
production of immunomodulatory cytokines, suggesting that the lung tissue environment itself 
may contribute to immunoregulatory T cell responses.  The study of T cells during a heterosubtypic 
challenge revealed enhanced in situ IL-10 production by CD4+ T cells in the lung resident niche.  
The blockade of IL-10 signaling during IAV secondary challenge led to increased IFN-ɣ and TNF-
α levels in the airway, demonstrating that IL-10 signaling plays an important role in the 
suppression of inflammatory immune responses.  Whole lung tissue transcriptional analysis was 
performed for primary and secondary infections compared to their uninfected baselines; secondary 
innate immune responses were significantly dampened, particularly for type I interferon responses, 
and upregulated significantly fewer genes.  Our findings suggest that lung localized T cell 
responses produce increased levels of immunomodulatory cytokines to minimize 




Chapter 2: Materials and Methods 
2.1: Influenza virus preparation and murine infection 
PR8, PR8-OTII, PR8-OTI, and X31 influenza virus were grown using chicken eggs.  Fresh 
and fertilized specific pathogen-free (SPF) chicken eggs (Charles River laboratories) were 
incubated at 37C at 40-60% humidity for 10 days.  Eggs were inspected for viable embryos using 
an egg candler.  Under sterile conditions, a hole was made in the shell above the air space using 
an 18 gauge needle.  200 L of influenza virus diluted in PBS (103-104 pfu/mL) were injected into 
the allantoic cavity, and the hole was covered with masking tape.  Eggs were then returned to the 
incubator and incubated for 48 hours at 37 ºC.   After 48 hours, eggs were moved to 4 ºC overnight.  
The shell covering the air space was cut away, and allantoic fluid was collected, aliquoted, and 
stored at -80 ºC for long term storage.   
To prepare influenza virus for infection, frozen aliquots were thawed on ice and diluted in 
ice cold PBS as determined by the stock concentration and desired infection titer, which is 
determined as described below in Section 2.2.  Diluted influenza virus stock was used soon as 
possible for murine inoculation.  Mice were anesthetized in 3.5% isofluorane using a rodent 
anesthesia machine and inoculated with 30 L of viral solution by allowing mice to breathe in the 
fluid from a pipette tip.   
 
2.2: Influenza viral titer determination 
In order to determine the viral concentration of a given sample, influenza virus was 
quantified using a Madin-Darby canine kidney (MDCK) cell line culture assay.  MDCK cells are 
an adherent kidney epithelial cell line that is susceptible to influenza virus and provide a 
mammalian cellular substrate for viral propagation.  Viral samples were serially diluted five-fold 
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in a U-bottom 96 well plate in 100 µL of Dulbecco’s Modified Eagle Medium (DMEM) containing 
5% heat-inactivated fetal bovine serum (FBS) and 500 µg/mL of L-glutamine-penicillin-
streptomycin supplement.  Three to four replicates per dilution were plated.  MDCK cells were 
detached from culture plates with trypsin and resuspended at a concentration of 2.5 × 105 cells/mL.  
100µL of MDCK cells were added to each well and plates were incubated in 37 ºC for 18-24 hours.  
Media was aspirated from the plates and replaced with 200 µL/well of serum-free DMEM with 
0.0002% trypsin, whose protease activity supports the internalization of virus into MDCK cells.   
After 4 days of 37 ºC incubation, 50 µL of 0.5% washed chicken red blood cells diluted in 
PBS were added to each well and allowed to incubate at room temperature for 1 hour.  The presence 
of influenza virus leads to HA-mediated hemagglutination of red blood cells that is manifested by 
an absence of a pellet in the bottom of the well.  The median tissue culture infectious dose (TCID50) 
was determined from these results using the Reed-Muench method. 
 
2.3: Proliferation dye labeling and transgenic T cell isolation and transfer 
 In order to label donor T cells with eFluor 450 proliferation dye (ThermoFisher), whole 
splenocytes were isolated and labeled with the dye as outlined in the manufacturer’s directions.  T 
cells were then isolated from labeled and rinsed splenocytes using magnetic CD4+ or CD8+ T cell 
negative isolation (Stemcell Technologies).  5×104 transgenic T cells were adoptively transferred 
into each mouse by retroorbital injection one day prior to PR8-OTI or PR8-OT-II challenge.  
 
2.4: Mouse tissue digestion and cellular isolation 
Lung tissue was enzymatically digested in order to isolate both lymphocyte and myeloid 
cell populations.  Digestion media was 20 ug/mL Liberase TM (Roche) in DMEM.  Lung lobes 
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were minced into chunks and added to gentleMACS C tubes (Miltenyi) containing 10 mL of 
digestion media where they were physically dissociated using gentleMACS Spleen 4.01 program.  
The resulting cell suspension was incubated in a 37 ºC shaker for 45 min – 1 hour and then 
mechanically dissociated again using gentleMACS Spleen 4.01 program.  The resulting cell 
suspension was then passed through a 70 µM filter. 
To process lymph nodes, lymph nodes were minced using a blade and incubated in 2 mL 
of digestion media for 20 minutes in a 37 ºC shaker.  Lymph node suspension was pipetted up and 
down using a 1 mL pipette in order to further physically dissociate cells.  After allowing undigested 
cellular debris to settle, supernatant was removed and added to 10% FBS DMEM on ice.  
Remaining cellular debris was resuspended in 1 mL of digestion media and added back to a 37 ºC 
shaker and the process was repeated until lymph nodes were completely digested.  Spleen was 
minced and incubated in digestion media in a 37 ºC shaker for 30 minutes and mechanically 
dissociated through a 70 µM filter.  If only T cells were needed, lymph nodes and spleen were 
passed through a 70 µM filter by manual mechanical dissociation technique in complete DMEM.   
 
2.5: In vivo labeling 
In order to distinguish tissue resident from circulating leukocytes, 2.5 µg of fluorescent 
antibody was injected into mice 3-5 minutes prior to sacrifice.  Antibody used was specific for 





2.6: Flow cytometry staining protocol 
Fluorescent antibodies, TruStain FcX (Biolegend), and BD Horizon™ Fixable Viability 
Stain 700 (BD Biosciences) were diluted in FACS buffer (1% fetal bovine serum in PBS).  Surface 
antigen staining of cells was performed in FACS buffer for 30 minutes at room temperature.  Cells 
were rinsed in FACS buffer and then fixed for 10 minutes in Cytofix buffer (BD Biosciences) 
before resuspension in FACS buffer and storage at 4C away from light sources.  Cells were 
analyzed within 72 hours of fixation. In the case of staining for BrdU, Phaseflow BrdU kit 
(Biolegend) was used according to the manufacturer’s protocol and recommendations.  Staining 
for surface molecules was also performed for 30 to 45 min at room temperature in the dark.  Stained 
cells were analyzed using a BD LSRII (BD Biosciences) flow cytometer and analyzed using 
FlowJo V10 (Tree Star, Inc., Ashland, OR).  
For cell sorting, staining was performed similarly, but in sorting buffer which was 
composed to FACS buffer with 5 mM EDTA.  Cells were sorted using a BD Influx high-speed 
sorter and into 5 mL tubes containing 1 mL of DMEM with 10% FBS.  List of fluorescently-





Table 2.1: List of antibodies used for flow cytometry 









































































2.7: FTY720 treatment 
FTY720/Fingolimod (Sigma) was diluted in normal saline and injected intraperitoneally 
daily into mice (200 µL/mouse) at a dose of 1mg/kg body weight.  FTY720 treatment was initiated 
2 days prior to heterosubtypic challenge and maintained throughout secondary infection.   
 
2.8: OT-II RAG-/- memory mouse generation 
Whole splenocytes were isolated from OT-II mice and purified for OT-II cells using a 
magnetic CD4+ T cell negative isolation kit (Stemcell Technologies).  T cells were cultured with 
OVA323-339 peptide (1 µg/mL) in complete RPMI (10% FBS) in U-bottom 96 well plates (5×10
4 
cells/well) for 5 days.  Resultant expanded T cells were adoptive transferred into RAG1-/- mice 
(106 OT-II cells/mouse) by intraperitoneal injection.  After 4 weeks, lung and spleen cells isolated 
for antigen-specific memory T cell responses  
 
2.9: In vitro T cell peptide stimulation and cytokine analysis 
In order to stimulate OT-II lung TRM, whole lung cells were isolated as described and 
cultured in complete DMEM (10% FBS) with varying concentrations of OVA323-339 for 24 hours 
in 105 cells/well in a 96 well U-bottom plate.  To activate OT-II lung TRM and spleen TEM with 
antigen presenting cells, CD4+ CD44+ CD62L- T cells were sorted from the lung or spleen of 
OT-II RAG1-/- memory mice.  5×104 sorted memory T cells were co-cultured with equal 
numbers of lung or spleen cells from RAG1-/- mice in a 96 well U-bottom plate in complete 
DMEM with varying concentrations of OVA323-339 for 24 hours.  Supernatant was stored at -80C 
and analyzed using a LEGENDPlexTM Mouse Th Cytokine Panel (Biolegend) cytometric bead 





2.10: αIL-10R antibody blockade 
 One day prior to influenza challenge, mice were intraperitoneally injected with 0.4 mg 
and intranasally administered 0.2 mg of αIL-10R antibody (Bio X Cell).  Two days after IAV 
challenge, αIL-10R antibody treatment was repeated.  Bronchoalveolar lavage (BAL) washes 
were isolated for cytokine analysis five days after IAV challenge. 
 
2.11: Generation of zbtb46-DTR bone marrow chimeras 
CD45.1+/+ C57BL/6 mice were irradiated with 1100-1200 rad by gamma irradiation in a 
secure CUMC facility.  Bone marrow cells were isolated and filtered in HBSS from femurs and 
tibias of sex-matched CD45.2+/+ zbtb46-DTR-/+ mice, and 107 cells were i.v. injected into each 
irradiated mouse.  Mice were maintained on water containing antibiotic (2mg/mL neomycin) for 
one week after irradiation, and allowed to recover for 10 weeks after irradiation for immune 
reconstitution. 
 
2.12: Diphtheria toxin preparation and administration 
Unnicked diphtheria toxin (List Biologicals) was reconstituted at 1mg/1 mL in PBS and 
aliquoted and stored at -80C.   Mice were injected i.p. at a dose of 40 ng/g two days prior to 
secondary challenge, and administered i.n. 50µL (12ng/µL) one day prior to secondary challenge. 
 
2.13: RNA Sequencing and Analysis 
Zbtb46-GFP cDC RNA Sequencing and analysis 
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CD45+ Zbtb46+ CD11c+ I-A/I-Ehi dendritic cells were FACS-sorted from the medLN cells 
of either naïve and memory mice. However, the number of medLN cDCs from uninfected naïve 
was extremely low.  Therefore, each biological replicate of naïve cDCs was sorted from the 
combined medLN cells of three different naive mice.  On the other hand, medLN from memory 
mice contained significantly more cells, so an individual mouse was sufficient to produce a single 
biological replicate.  Sorted cells were spun down immediately in ice cold PBS and resuspended 
in Trizol.  RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen) and quantitated 
using an Agilent 2100 Bioanalyzer (Agilent Technologies).   
For low input sequencing, RNA-Seq libraries were prepared and sequenced by the CUMC 
Genome Center using SMART-seq v4 Ultra Low Input RNA kit (Takara Bio USA) to create 
amplified cDNA and Nextera XT kit (Illumina) for library preparation.  Libraries were sequenced 
on the Illumina Novaseq 6000 at the Columbia Genome Center. RNA-Seq reads were mapped 
using Kallisto (v.0.44.0) with default parameters to the mouse reference genome build GRCh38.  
Non-protein coding genes were filtered out, and then the bottom third of genes were filtered out 
by their gene counts. Differential gene expression analysis was then performed with DESeq2 using 
variance stabilized transformation to generate normalized gene expression data. Genes with 
Padj≤0.05 and absolute value of fold change≥2 were considered to be differentially expressed.  Heat 
map was generated from transcripts per million (tpm) counts generated from kallisto 
pseudoalignment.  Data are available on Gene Expression Omnibus (GSE144755) 
 
Whole lung tissue RNA Sequencing and analysis 
 Age-matched 12-16 week old C57BL/6 naïve and X31 memory mice were initiated daily 
FTY treatment.  After two days of FTY treatment, half the mice were then challenged with 
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intranasal PR8 IAV (TCID50 2000). Two days later, all mice were euthanized and lungs were 
perfused with PBS.  After blotting away excess water, the right lung lobe of each mouse was 
isolated and flash frozen in liquid nitrogen.  RNA was extracted from frozen tissue using 
QIAsymphony (Qiagen) instrument and quantitated using an Agilent 2100 Bioanalyzer (Agilent 
Technologies) by the CUMC molecular pathology core.  cDNA libraries were prepared by the 
CUMC Genome Center using a poly-A pulldown to enrich mRNA and subsequent Illumina 
TruSeq RNA prep kit.  Libraries were sequenced using Illumina HiSeq 4000.  RNA-Seq reads 
were mapped and quantified using Salmon (v.0.9.1) to the mouse reference genome build 
GRCh38.  Differential gene expression analysis was performed with DESeq2 using variance 
stabilized transformation to generate normalized gene expression data. Heat map was generated 
using FPKM data of differentially expressed genes. Scatter plot generated using normalized counts 
with an average count greater than 10.   
 In order to analyze the functional relevance of differential expressed genes of both primary 
and secondary responses, Ingenuity Pathway Analysis (IPA) by Qiagen was used.  A matrix 
containing differentially expressed genes as well as associated information such as fold changes, 
expression levels, p-values, and FDR values as determined by DESeq2 analysis was uploaded to 
the IPA software.  We uploaded two matrices: one for primary infection and one for secondary 
infection.  Pathway analysis was performed by proprietary IPA algorithms which reveal biological 
pathways that are enriched within the differentially expressed geneset.   
 Gene set enrichment analysis (GSEA) was performed using GSEA (v4.0.3) software 
provided by the Broad Institute [163, 164].  Gene lists for primary and recall responses were 
determined by DESEq2 analysis with a padj<0.05.  Differentially expressed genes were inputted 
into .rnk files, listing gene names and their respective log2 fold changes.  Gene lists were ranked 
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by their fold change.  These gene lists were inputted into GSEA software using a weighted scoring 
scheme to an expression dataset c7.all.v7.1.symbols.gmt [Immunologic signatures] with 1000 
permutations based upon the pathway phenotypes.  The collapse parameter was selected during 
analysis.   Chip platform “Mouse_ENSEMBL_Gene_ID_to_Human_Orthologs_MSigDB.v7.1” 
was used to assess the gene set enrichment of our findings to various transcriptional analysis in 
human cells.  Significantly enriched gene sets were analyzed for their relevance to antiviral 
immunity.   
 
2.14: Mouse strains 
C57BL/6J (B6 WT, stain number 000664), B6.SJL-PtprcaPepcb/BoyJ (CD45.1, strain 
number 002014), C57BL/6-Tg(TcraTcrb)1100Mjb/J (OT-I, strain number 003831), 
B6.Cg-Tg(TcraTcrb)425Cbn/J (OT-II, strain number 004194), B6.129S2-Ighmtm1Cgn/J (µMT, 
strain number 002288), B6.129S6(C)-Zbtb46tm1.1Kmm/J (zbtb46-GFP, strain number 027618), 
B6(Cg)-Zbtb46tm1(HBEGF)Mnz/J (zbtb46-DTR, strain number 019506), B6.129S6-Il10tm1Flv/J (IL-
10-GFP tiger, strain number 008379), B6.129S7-Rag1tm1Mom/J (Rag1 KO, strain number 002216) 
mice were purchased from the Jackson Laboratory or bred and maintained under specific 
pathogen–free conditions in a BSL2 biocontainment room within Columbia University Medical 
Center (CUMC) animal facilities. 
 
2.15: Statistical Analysis 
Statistical analyses were performed in GraphPad Prism (v.8.0.0).  Significance tests as well 




Chapter 3: Influenza infection imprints local lymphoid sites to promote lung resident 
heterosubtypic immunity  
 
3.1: Abstract 
Influenza infection generates tissue-resident memory T cells (TRM) that are maintained in 
the lung and can mediate protective immunity to heterologous influenza strains, though the precise 
mechanisms of local T cell-mediated protection are not well understood.  In a murine 
heterosubtypic influenza challenge model, we demonstrate that protective lung T cell responses 
are independent of B cell responses, and derive from in situ activation of tissue resident memory 
T cell (TRM) and the enhanced generation of effector T cells from the local lung draining 
mediastinal lymph nodes (medLN).  Primary infection fortified the medLN with an increased 
number of conventional dendritic cells (cDC) that mediate enhanced priming of T cells, including 
those specific for newly encountered epitopes; cDC depletion during the recall response 
diminished medLN T cell generation and heterosubtypic immunity. Our study shows that during 
a protective recall response, cDC in a fortified LN environment enhance the breadth, generation, 






Diseases of the respiratory tract, triggered by diverse viral and bacterial pathogens that 
repeatedly infect individuals over their lifetimes, remain the leading cause of morbidity and 
mortality worldwide.  Influenza virus is a major public health burden that globally causes up to 5 
million cases of severe disease and 650,000 deaths each year, causing the most severe disease 
manifestations in children and the elderly [165].  Influenza vaccines target generation of strain-
specific neutralizing antibodies and remain poorly efficacious, resulting in seasonal outbreaks of 
unpredictable severity. T cells however, can recognize invariant determinants of influenza present 
in all strains and mediate efficacious cross-strain protection in mouse models [166]. Moreover, T 
cell clones recognizing different influenza strains are readily detectable in human blood [167-169], 
indicating that promoting T cell-mediated immunity is a promising strategy for generating broad-
based protection in the population.  
Recent studies have shown that tissue localization is an important factor for T cell-mediated 
protective immunity, particularly in the respiratory tract.  During a primary influenza infection, T 
cell responses are primed by dendritic cells (DC) that migrate from the lung to the draining lymph 
node (LN) and present influenza antigens to naïve T cells [60], resulting in the generation of lung-
homing CD4+ and CD8+ effector cells to mediate viral clearance. Heterogenous subsets of memory 
T cells are generated from this initial infection and persist in multiple tissue sites, including non-
circulating tissue resident memory T cells (TRM) within the lung [94, 104, 170]—a distinct subset 
that is present in multiple tissues in mice and humans and is transcriptionally and functionally 
distinct from circulating effector-memory (TEM) cells [97, 171, 172].  Lung CD4+ and CD8+ TRM  
mediate efficacious protection including lung viral clearance and reduced morbidity to 
heterosubtypic influenza strains [94, 104, 119, 173, 174].  Functionally, lung TRM can be activated 
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in situ in the presence of inhibitors of lymphoid egress [104], and TRM in the airways can mediate 
protection through effector cytokine production [119]. While these studies suggest that TRM in 
the tissue site of infection may dominate secondary responses, the contribution and requirements 
for circulating or lymphoid T cell populations during the recall response and specifically in the 
lung, are not clear.  
Here, we demonstrate in a mouse model of heterosubtypic protection that lung T cells 
exhibit local protective responses to challenge with a heterologous viral strain, independent of B 
cells and humoral immunity. This local recall response involves both in situ lung TRM 
proliferation and recruitment of effector T cells from the periphery. Using a T cell tracking model, 
we demonstrate that in previously infected mice, priming of T cells in the medLN DC leads to 
rapid generation and trafficking of effector T cells to the lung resident niche, including those T 
cells specific for influenza antigens newly introduced during heterosubtypic challenge. We further 
demonstrate that enhanced T cell priming and generation was due to the fortification of medLN 
from the previous infection, marked by increased numbers of conventional DC (cDC). Preferential 
ablation of cDC in the medLN during heterosubtypic challenge abrogated enhanced T cell priming 
and inhibited the protective response. Therefore, the lung T cell-mediated recall response is 
comprised of robust effector generation from fortified local LN which coordinates with lung TRM 




Lung niche T cells mediate protective responses to heterosubtypic influenza infection 
independent of B-cells 
We assessed the differentiation and migratory state of T cells in the lung and draining 
mediastinal lymph node (medLN) from mice previously infected with influenza 3-4 weeks prior 
(“memory”) mice compared to uninfected (“naïve”) mice (Fig. 3.1 A). Intravenous antibody 
labeling was used to distinguish between T cells in circulation that become labeled by antibody 
from those cells in the tissues that are protected from antibody binding, as previously described 
[104]. Memory mice had significantly increased frequencies and numbers of protected CD44hi 
CD4+ and CD8+ T cells in the lung tissue niche (Fig. 3.1 A), which were enriched for influenza-
specific T cells shown by tetramer staining of CD8+ T cells (Fig. 3.2), consistent with our previous 
findings that lung niche T cells are a surrogate for antigen-specific responses [104].  Lung niche 
CD44hi memory T cells expressed CD69 (for CD4 and CD8) and CD103 (for CD8) (Fig. 3.1 B), 
consistent with a TRM phenotype [90, 101, 104, 174]. The lung-draining medLN also contained 
increased numbers of CD44hi CD4+ and CD8+ T cells compared to uninfected naive mice, and a 
minor subset also expressed TRM markers (Fig. 3.1 C). These results show a robust, quantifiable 
generation of lung TRM and local lymphoid memory T cells following influenza infection that is 




Figure 3.1: Influenza infection generates memory CD4+ and CD8+ T cells in the lung tissue 
niche and draining lymph node. 
T cells were isolated from the lung and lung-draining mediastinal lymph node (medLN) of 
uninfected “naïve” mice and “memory” mice (infected with X31 influenza 3-4 weeks previously), 
following intravenous administration of anti-CD45.2 antibody (see methods).  (A) Analysis of lung 
T cells shown in representative flow cytometry plots of CD44 expression by circulating labeled 
(red) and lung tissue niche (blue) CD4+ and CD8+ T cells (left), and graphs of numbers of lung 
niche CD44+ CD4+ and CD8+ T cells in individual naïve and memory mice (right). Data compiled 
from 2 groups, n=5-6 mice/group.  (B) Lung niche T cells from memory mice express surface 
TRM markers. Expression of CD69 and CD103 expression by lung niche (blue) versus circulating 
(labeled, red) T cells shown as representative histograms (left) and graphs showing individual mice 
(right) treated with FTY720 for two days.  Data compiled from two independent experiments, n= 
7 mice/group. (C) Increased memory T cells in the medLN persist after primary influenza 
infection. Left: Representative flow cytometry plots of CD44 and CD69 expression by medLN 
CD4+ and CD8+ T cells from naïve and memory mice treated for 2 days with FTY720. Right: 
absolute numbers of medLN CD44+T cells shown for individual naïve and memory mice.  Data 
compiled from 2 independent experiments.  n= 7 mice/group.  Significance determined using 









Figure 3.2: Primary infection generates influenza-specific local memory T cells  
Lung and medLN cells isolated from mice infected 3-5 weeks after primary infection.  Left: Flow 
cytometry plots gated on lung CD44+ CD8+ showing NP-tetramer expression by lung niche (blue) 
and labeled (red) cells and graph showing number of lung CD44+ CD8+ NP-Tet+ cells.  Right: Flow 
cytometry plots gated on medLN CD44+ CD8+ showing CD103 and NP-tetramer expression and 
graph depicting absolute number of medLN CD44+ CD8+ NP-Tet+ T cells. Data representative of 
2 experiments, n=4 mice/group.  Significance determined by student’s unpaired t-test.  ****, 













We used a modified mouse model of heterosubtypic immunity to assess mechanisms for T 
cell-mediated recall to influenza infection in the context of a polyclonal T cell response. Naïve and 
memory mice previously infected with the X31 (H3N2) strain of influenza virus were treated with 
the sphingosine-1-phosphate receptor (S1PR1) agonist FTY720 prior to and during challenge with 
the heterosubtypic PR8 (H1N1) strain of influenza in order to minimize the contributions of 
circulating cells at the time of challenge; protective immunity (morbidity and viral clearance) was 
measured at sequential timepoints post-challenge compared to primary influenza infection of naïve 
mice (Fig. 3.3 A, B).  In the presence of FTY720 which selectively reduces the number of 
circulating (labeled) T cells in the lung but maintains TRM in the lung niche (Fig. 3.4 A) [104, 
174], memory mice exhibited significantly reduced weight-loss morbidity over the course of 
infection compared to primary infection of naïve mice, and significantly lower lung viral load at 6 
days post-infection (Fig. 3.3 B), the timepoint of peak viral load for primary infection [175]. The 
generation and localization of lung T cells in the lung tissue niche during maintenance with 
FTY720 treatment were similar in µMT mice which lack mature B cells [176] compared to WT 
memory mice (Fig. 3.4 B).  Notably, reduced morbidity and near-complete viral clearance was 
also observed in µMT memory mice compared to primary infection of µMT naïve mice (Fig. 3.3 
C). These data provide evidence that local T cell memory directs protective immunity with the 




Figure 3.3:  T cell-mediated protection to heterosubtypic challenge is tissue-localized and 
independent of B cells.  
(A) Schematic diagram depicting heterosubtypic challenge model in which uninfected naïve mice, 
and memory mice, generated from prior X31 infection, are simultaneously challenged with PR8 
(H1N1) virus with concurrent FTY720 treatment to compare primary and recall immune responses 
when systemic responses are inhibited.  (B) Left: Weight loss morbidity at indicated times post-
challenge during primary and recall infection. Right: Viral titers assessed in the bronchioalveolar 
lavage (BAL) on day 6 post-challenge.  Data compiled from 2 independent experiments, n=10-12 
mice/group. (C) Weight loss morbidity and BAL viral titers after PR8 challenge of B-cell-deficient 
(µMT) naïve and memory mice. Viral titers determined at Day 7 post-infection.  Data compiled 
from 2 experiments, n=10-14 mice/group. Significance was determined by student’s unpaired t-
test.  Log10 of viral titers TCID50/mL was compared by t-test to determine significance. ****, 








Figure 3.4: Local resident memory persists after FTY720 treatment  
(A) Lung T cells isolated from wild type C57BL/6 mice after 3-4 weeks post-X31 infection and 
either treated with FTY720 or PBS control for two days and intravenously labeled with CD45.2 
fluorescent antibody.  Compiled from 4 independent experiments, n=5-7 mice/group.  
Significance determined by student’s unpaired t-test.  **, p≤0.05, *, p<0.05. Error bars are mean 
± SEM. (B) Representative FACS plot of lung (left) and medLN (right) T cells isolated from 









Expansion of CD103- negative T cells within the lung resident niche and medLN during 
recall 
We investigated how the lung T cell dynamics in the recall response differed from that in 
the primary response.  After PR8 challenge, the numbers of CD4+ and CD8+ CD44hi T cells within 
the lung resident niche significantly increased at 4-5 days post-infection in memory mice (recall) 
to levels fivefold higher than the number of lung niche T cells in the primary response (primary) 
(Fig. 3.5 A). By contrast, circulating lung CD4+ and CD8+ T cells identified by in vivo Ab labeling 
did not increase in number after infection (Fig. 3.5 A), revealing that the enhanced and rapid T cell 
accumulation during recall is specific to the lung tissue niche. T cell proliferation during recall 
was further assessed by harvesting lung T cells two hours following in vivo BrdU administration.  
BrdU+ CD4+ and CD8+ T cells were detectable 4-5 days post-challenge predominantly in the lung 
resident niche, and not within circulating (labeled) cells (Fig. 3.5 B) and were minimally affected 
by FTY720 treatment (Fig. 3.6). Together, these findings demonstrate that the increase in lung T 
cell numbers during the recall response was due, at least in part, to proliferating T cells localizing 
in the lung resident niche. 
The accumulation of proliferating T cells in the lung tissue niche could derive exclusively 
from lung TRM, or also involve migration of T cells from the periphery during FTY720 treatment. 
We therefore assessed lung T cell numbers and BrdU incorporation based on CD103 expression 
as a TRM marker, as CD69 expression can vary during the course of infection [104].  Notably, 
CD103- and not CD103+ T cells were the major subset accumulating in the lung resident niche for 
both CD4+ and CD8+ T cells, albeit lower frequencies of lung CD4+ TRM express CD103 
compared to CD8+ TRM (Fig. 3.5 C). Furthermore, CD103- CD8+ lung T cells incorporated BrdU 
to a greater extent than their CD103+ TRM counterparts (Fig. 3.5 D), suggesting that enhanced 
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proliferation may underly their increased accumulation in the lung niche. (Similar BrdU analysis 
for CD4+ cells was not performed due to low CD103+ numbers).  The predominant expansion of 
CD103- rather than CD103+ lung T cells during recall suggested a potential influx of T cells from 
the periphery, prompting examination of proliferation within local lymphoid sites.  
In the local medLN of memory mice, CD4+ and CD8+ T cells exhibited rapid accumulation 
at 3-4 days post-challenge, resulting in peak numbers 5 to 10-fold greater than during primary 
infection (Fig. 3.7 A, Fig. 3.8 A).  Importantly, the expanded medLN T cells during recall were 
predominantly non-TRM, CD44hiCD62LloCD103- (effector-memory) cells (Fig. 3.7 B). 
Accordingly, BrdU incorporation was significantly higher in the recall response compared to the 
primary response for proliferating medLN CD44hiCD62Llo T cells and was largely observed in the 
CD103- TEM rather than the CD103+ TRM subset (Fig. 3.7 C).  No significant BrdU incorporation 
was observed in memory CD4+ or CD8+ T cells in the spleen at these timepoints, demonstrating 
this lymphoid-derived proliferation was locally regulated (Fig. 3.8 B). These data demonstrate 




Figure 3.5:  Heterosubtypic recall promotes rapid accumulation and proliferation of lung 
niche CD103- T cells  
Lung T cells were isolated from naïve and memory mice challenged as in Fig. 3.3, following 
administration of BrdU i.p. and i.n. 2 hrs prior to tissue harvest. (A) Accumulation of CD44+ 
CD4+(upper) and CD8+ (lower) T cells in the lung niche following primary and recall challenge 
shown in representative flow cytometry plots (left), and in graphs depicting absolute numbers of 
lung niche (middle) and labeled (right) CD44+ T cells.  (B) Flow cytometry plots (left) gated on 
lung T cells showing BrdU incorporation by lung niche and labeled cells, and graphs depicting 
absolute numbers of CD44+ CD4+ (middle) and CD8+ lung niche (blue) and labeled (red) BrdU+ T 
cells.  (C) Flow cytometry plots (left) depicting CD103- and CD103+ CD44+ CD4+ and CD8+ lung 
T cell accumulation during the recall response.  Graphs show absolute numbers of lung niche 
CD44+ CD4+ (middle) and CD8+ (right) T cells during recall response.  (D) Lung CD8+ T 
cell BrdU incorporation during the recall response, depicted by representative flow cytometry plot 
(left) of CD44+CD8+ lung niche T cell BrdU expression and a graph showing number of BrdU+ 
lung niche CD103- and CD103+ CD44+ CD8+ T cells.  All data is representative of two independent 







Figure 3.6: FTY720 treatment does not block T cell migration to lung niche 
T cells were isolated from the lungs of memory and naïve mice 5 days after PR8 challenge with 
or without daily FTY720 treatment.  Left: Representative flow plot of CD4+ and CD8+ lung T cells 
showing CD44 expression plotted against in vivo injected CD45.2 expression.  Right: Histograms 
depicting number of CD44+ CD4+ or CD8+ T cells either labeled or protected by in vivo 
fluorescent antibody.  Graphs show mean ± SEM (n=4-5 mice per group; significance between 










Figure 3.7. The recall response enhances accumulation and proliferation of medLN T cells 
MedLN T cells were isolated from naïve and memory mice challenged and treated with BrdU 
during FTY720 treatment as in Figure 3.5.  (A) Absolute numbers of medLN CD44+ CD4+ and 
CD8+ T cells during primary and recall responses to PR8 challenge. (B) Similar to (A) except 
CD44+ T cells during only the recall response were stratified into CD103+ and CD103- cells. (C) 
BrdU incorporation by CD103+ and CD103- CD44+CD62L- CD4+ (top) and CD8+ (bottom) T cells 
in the primary and recall response shown in representative flow cytometry plots (left) and graphs 
(right) showing the percent BrdU incorporation from individual mice 4 and 5 days post-challenge.   
All data is representative of 2 independent experiments, n=2-4 mice/group. *, p≤0.05 as 







Figure 3.8: Lymphoid T cell expansion during recall response 
(A) Total medLN CD4+ and CD8+ T cell counts (B) Spleen CD4+ and CD8+ CD44+ CD62L- 
relative BrdU incorporation proportions.  Data representative of two experiments, n=2-3 










Enhanced T cell priming to new epitopes in the secondary response drives effector 
migration to the lung resident niche 
In order to assess the contribution of peripheral T cell activation and migration to the  lung-
localized recall response, we adoptively transferred naïve CD4+ CD44- CD45.1+ OT-II cells 
expressing a transgene-encoded TCR specific for ovalbumin peptide (OVA) into naïve and 
memory mice which were subsequently challenged with recombinant PR8-OTII or PR8 as a 
control (Fig. 3.9 A).  In response to PR8-OTII challenge, OT-II cells exhibited enhanced 
recruitment to the lung in memory compared to naïve hosts; there were increased frequencies and 
numbers of OT-II cells in the lung, lung resident niche, medLN, and spleen, at 5 days post-infection 
in memory mice compared to negligible-to-low numbers of OT-II cells during primary infection 
(Fig. 3.9 B). Minimal numbers of OT-II cells were detected in the inguinal lymph node (ILN) 
distal to the infection site in naïve or memory hosts following PR8-OTII challenge, indicating that 
priming of OT-II cells occurred local to the infection site. Moreover, OT-II cells were minimally 
present in tissues during primary or recall challenge with PR8 lacking the OVA epitope (Fig. 3.9 
B), indicating that bystander migration was not sufficient to recruit and/or activate significant 
numbers of OT-II cells.  During the recall response, lung OT-II cells incorporated more BrdU+ 
compared to their polyclonal host CD4+ T counterparts following PR8-OTII heterosubtypic 
challenge (Fig. 3.9 C), demonstrating robust activation and in situ proliferation of the OVA-
specific T cells, similar to what was observed in the lung polyclonal T cell response (Fig. 3.5 B).   
In addition, because we observed increased CD8+ polyclonal T cell responses as well, we 
interrogated whether these same findings would apply to OT-I cells.  We also transferred naïve 
OT-I CD8+ T cells into naïve and memory mice and challenged mice with PR8-OTI in the same 
way as performed for OT-II cells (Fig. 3.9 B).  Five days after challenge, we observed a significant 
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increase in CD8+ OT-I numbers in the medLN, similar to what was observed for CD4+ OT-II 
responses.  However, we were also unable to find significant differences in the lung, perhaps due 
to differences in T cell migration kinetics using the PR8-OTI model. Together, these results show 
enhanced activation, proliferation and lung-specific migration of newly-primed, flu-specific CD4+ 
and CD8+ effector cells in the presence of an ongoing recall response to influenza.  
Because B-cells are a major antigen presenting cell, we investigated whether expansion 
and migration of OT-II cells during the recall response also occurred in µMT memory mice.  
Similar to results in B-cell competent WT hosts, OT-II cells were present in the lung resident 
niche, medLN, and spleen in significantly greater numbers in memory µMT mice compared to 
naïve µMT mice at 4-5 days post-challenge with PR8-OTII (Fig. 3.10 A and B).  OT-II cells were 
present in greater numbers in the medLN compared to the spleen at day 4 post-infection, suggesting 
that the medLN is the primary initiating priming site (Fig. 3.10 A).  Moreover, OT-II expansion 
and migration occurred independently of FTY720 treatment (Fig. 3.11), suggesting that while 
FTY720 treatment may reduce non-specific bystander T cell migration (Fig. 3.9 B), migration 
from local lymphoid sites is unaffected. These results show that local recall responses are 
associated with enhanced generation of effector T cells from the local draining lymph node 





Figure 3.9: Recall response enhances local lymph node T cell priming and migration to the 
lung tissue niche 
(A) Experimental schematic for tracking new effector and circulating T cell responses: CD44lo 
CD45.1+ OT-I or OT-II  T cells were transferred into naïve and memory mice (WT or MT), which 
were subsequently challenged with PR8 or recombinant PR8-OTI/OT-II in the presence of 
FTY720 treatment, and tissues were harvested day 4-5 post-infection following intravenous 
administration of anti-CD45.2 Ab.  (B)  T cells isolated from lung, medLN, spleen, and ILN of the 
indicated hosts and challenge conditions were assessed for the presence of OT-II (CD45.1+) CD4+ 
T cells shown in representative flow cytometry plots (left, OT-II containing quadrants outlined in 
green), and in graphs depicting total numbers of OT-II cells in each tissue site for individual mice.  
Data are representative of two independent experiments, n=3-5 mice/group/experiment.  (C) BrdU 
incorporation by lung OT-II cells and CD45.1- host polyclonal cells 5 days after recall challenge 
with PR8-OTII. Data representative of two independent experiments, n=3-5 
mice/group/experiment.  (D) OT-I cells in the lung and medLN of wild type hosts following 
primary or recall challenge with PR8-OTI shown in representative flow cytometry plots (left), and 
graphs depicting total numbers of OT-I cells in each tissue site in primary or recall responses.  Data 
are representative of 2 independent experiments, n=3-5 mice/group/experiment.  Significance in 
(B) and (D) between primary and recall groups determined by student’s unpaired t-test.  
Significance in (C) determined by paired t-test between OT-II and polyclonal cells. ****, 







Figure 3.10: Enhanced medLN T cell priming in B cell-deficient mice 
CD44lo CD45.1+ OT-II indicator population is transferred into both naïve and memory µMT mice, 
and PR8-OTII challenge performed, and cells were isolated from lung, medLN, and spleen T cells 
after (A) 4 and (B) 5 days.  (A, B) Left: Representative flow cytometry plots gated on CD4+ T 
cells.  Right: Graph depicting number of OT-II cell in lung, medLN, and spleen. Representative of 
2 independent experiments, n=3-5 mice/group. Significance determined by student’s unpaired t-








Prior influenza infection fortifies local lymph nodes for T cell priming 
We hypothesized that the local LN environment in memory mice promoted activation and 
priming of new flu-specific effector cells. Following previous influenza infection, there was a 
marked increase in T cell numbers—both naïve and memory—even at 35 days post-infection (Fig. 
3.12 A), suggesting that local infection may confer preferential homing or retention of T cells in 
the medLN. Indeed, transfer of equal numbers of naïve OT-II cells into the different hosts, resulted 
in greater numbers of OT-II retained in medLN of memory compared to naïve mice (Fig. 3.12 B), 
indicating that the environment of medLN in previously infected mice enabled increased retention 
of T cells compared to uninfected mice.   
We then sought to clarify the degree to which the significantly increased medLN OT-II 
expansion during the recall response was due to a larger precursor population or enhanced 
activation and proliferation. At day 2 post-challenge with PR8-OTII, nearly all of the OT-II cells 
in the medLN of memory mice expressed the early TCR activation marker Nur77 (known to be 
induced several hours after TCR signaling [177, 178]), while OT-II cells in the spleen did not 
express Nur77 at this early timepoint (Fig. 3.12 C), demonstrating that the medLN is the initial 
site of influenza-specific T priming. By day 3 post-challenge, there was already extensive 
proliferation of medLN OT-II cells during the recall response compared to a significantly lower 
proliferation (and greatly reduced numbers) of medLN OT-II cells in the primary response (Fig. 
3.12 D).  These data demonstrate that prior influenza infection fortifies the local medLN to 




Figure 3.11: FTY treatment does not affect IAV-specific T cell lung migration  
CD44lo CD45.1+ OT-II indicator population is transferred into both naïve and memory mice and 
challenged with PR8-OTII.  Lung cells were isolated after 5 days post PR8-OTII challenge.  
Graph depicts number of lung CD4+ CD45.1+ OT-II T cells during the primary and recall 
responses with or without FTY720 treatment.  Data compiled from 2 independent experiments, 










Figure 3.12:  Enhanced naïve T cell recruitment, activation and proliferation in the medLN 
during the recall response 
(A) Prior influenza infection results in increased numbers of naïve and memory T cells in the 
medLN. Graphs show numbers of indicated CD4+ and CD8+ T cell subsets (T-naïve, CD44lo 
CD62Lhi; TEM, CD44hi CD62Llo; TCM, CD44int CD62Lhi) in the medLN of uninfected (naïve) 
mice and memory mice 3-5 weeks post-infection.  Data representative of 2 experiments, compiled 
from 3-5 mice per group. (B) Recruitment and/or retention of naïve OT-II CD4+T cells in medLN 
2 days following transfer of equal numbers (50k cells/mouse) into naïve and memory congenic 
mice as assessed by representative flow cytometry plots of transferred CD45.1+ CD4+ T  cells (left), 
and by graph (right) showing absolute numbers of  OT-II cells in naïve and memory mouse hosts. 
compiled from 4-5 mice/group.  (C, D) Enhanced priming in the medLN of memory mice during 
recall. Proliferation dye labeled OT-II/Nur77-GFP cells were transferred into naïve and memory 
mice hosts, and mice were subsequently challenged with PR8-OTII one day later. (C) Expression 
of the early TCR signaling molecule Nur77 as indicated by GFP expression by T cells isolated 
from medLN and spleen 2 days post-challenge shown in representative flow cytometry plots gated 
on OT-II cells (left), and graphs (right) showing frequency of GFP+ cells in the recall response.  
Data representative of 2 experiments, n= 3-5 mice/group.  (D) Enhanced proliferation in the recall 
response. Same setup as in (C) except T cells were isolated from medLN 3 days after PR8-OTII 
challenge.  Left: Representative flow cytometry plots gated show dilution of proliferation dye by 
OT-II cells. Graphs depict percentage of OT-II cells divided (middle)and total number of OT-II 
cells (right). Data shown are representative of two independent experiments, n=3 mice/group. 
Significance determined by student’s unpaired t-test, ***, p≤0.001; **, p≤0.01; *, p≤0.05).  Error 






Increased numbers of conventional dendritic cells persist in the medLN following influenza 
infection 
The more rapid priming of OT-II in the medLN of memory mice suggested that 
conventional dendritic cells (cDC), which prime naïve T cells, were altered in the medLN of 
memory compared to naïve mice. The number of medLN cDCs (CD45+ CD11c+ I-A/I-Ehi) 
increases within four days following primary infection, and both CD11b+ CD103- and CD11b
- 
CD103+ cDCs are present in increased numbers up to 35 days after primary challenge (Fig. 3.13 
A).  To better identify cDCs between sites, as CD11c can also be expressed by tissue macrophages 
[179], we assessed expression of the transcription factor zbtb46, which is specifically expressed by 
cDCs [180, 181], using zbtb46-GFP reporter mice [181]. Consistent with the CD11c results, zbtb-
46+cDCs are present in greater numbers specifically within the medLN of memory mice compared 
to naïve (uninfected) mice, while cDC numbers in the non-draining ILN are unchanged between 
naïve and memory mice (Fig. 3.13 B). Numbers of Lung cDC are also not significantly different 
between naïve and memory mice (Fig. 3.13 B). This quantifiable increase in cDC content that is 
induced from prior influenza infection, is therefore specific to the local lung-draining LN and not 
within the tissue site of infection.  
We examined the augmented medLN cDC population for qualitative functional changes, 
including markers of migration and activation.  Zbtb46+ cDCs from both the lung and medLN of 
memory mice contained higher proportions of CD11b- CD103+ migratory cells (Fig. 3.13 C), 
which also express higher levels of the costimulatory ligand and DC activation marker CD86 (Fig. 
3.13 D). (There was no change in the level of CD86 expression by either cDC subset between 
naïve and memory mice).  In an unbiased approach to identifying potential changes in medLN 
cDCs between naïve and memory mice, we analyzed the transcriptome profile of CD45+zbtb46+ 
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cDCs from the medLN of naïve and memory mice by RNAseq (Fig. 3.13 D).  Gene expression 
between the two cDC populations was highly similar with only 61 genes differentially expressed 
(Fig. 3.13 E) including the tissue residence marker Cxcr6, and chemokines Ccl6 and Ccl24, but 
without a clear signature of increased cDC activation or antigen presentation.  These data show 
increased numbers and migration of zbtb46+ cDC populations in the medLN of memory mice that 
are transcriptionally similar to their naïve counterparts, suggesting that the enhanced T cell priming 




Figure 3.13:  Influenza infection promotes long-term quantitative increases in cDC in the 
medLN 
(A) Number of lung-migratory cDCs in the medLN increases during influenza infection and 
persists. Left: Flow cytometry plots show frequency of cDC (CD11c+MHC Class II+) and lung-
migratory (CD103+CD11blo) cDC in the medLN at indicated timepoints after primary X31 
infection.  Right: Graph depicting absolute numbers of CD11b+CD103- and CD11b-CD103+ cDC 
in the medLN over the course of primary infection from 3-4 mice per group.  (B) Quantification 
of cDC using zbtb46-GFP reporter mice. Left: Flow cytometry plots show GFP expression in 
lung, medLN, and ILN CD45+ cells isolated from naïve or memory zbtb46-GFP mice.  Right: 
Graphs showing total number of zbtb46+ CD11chiI-A/I-Ehi cDC and proportion of 
zbtb46+ expressing CD45+ cells in lung, medLN, and ILN of naïve or memory mice, compiled 
from 4 experiments, n=6-12 mice/group. (C) CD103 expression of cDC using zbtb46-GFP 
reporter mice. Left: Flow cytometry plots of CD103 and CD11b expression by zbtb46-GFP+ 
cDCs from lung, medLN or ILN of naïve and memory mice.  Right: Graphs showing proportion 
of CD11b-CD1103+zbtb46-GFP+ cDCs compiled from 4 experiments, n=6-12 mice/group.  (D) 
CD86 and CD103 expression by medLN zbtb46-GFP+ cDC isolated from naïve and memory mice 
compiled from 3 experiments, n=9 mice/group.  (E) Whole transcriptome profiling by population 
RNA sequencing (RNAseq) of CD45+ zbtb46-GFP+ CD11c+ I-A/I-E+ cDCs sorted from medLN of 
naïve and memory mice as in (B).  Reads were mapped using Kallisto and DESeq2 was used to 
determine significantly differentially expressed genes by memory cDC compared to naïve cDC.  
Left: Volcano plot depicts genes by the absolute value of Log10Padj and the relative fold change 
comparing memory cDC against naïve cDC.  Genes that show differential gene expression of at 
least twofold change show in green, and genes with an absolute value of Log10Padj greater than 4 
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shown in red. Right: Heat map of top differentially expressed genes between naïve and memory 
cDCs based on transcripts per million (TPM) and determined by Padj ≤ 0.05 and mean fold 
difference ≥2.  Z-score based on standard deviation from mean TPM value per gene.  N=3 
mice/group.  For all experiments, significance between naïve and memory mice determined by 







Lymph node DC are required for protection and enhanced CD4+ and CD8+ T cell priming 
in the recall response 
To assess the role of increased cDC numbers in key features of the recall response, 
including protective immunity and enhanced CD4+ and CD8+ T cell priming within the medLN, 
we used a Zbtb46-DTR mouse model to deplete cDCs in vivo by diphtheria toxin (DT) 
administration.  Due to broad expression of zbtb46+ in non-hematopoietic cells [181], we generated 
bone marrow chimeras (B6.zDTR) using bone marrow cells derived from CD45.2+/+ zbtb46-DTR 
mice transferred into  lethally irradiated CD45.1+/+ host mice (Fig. 3.14 A, see methods). B6.zDTR 
mice were infected with X31 to generate memory mice as in Fig. 3.3 and  treated with DT to 
deplete cDC; OT-I or OT-II CD45.1+/CD45.2+ cells were subsequently transferred into both DT-
treated and untreated B6.zDTR memory mice which were challenged with PR8-OTI or PR8-OTII 
(Fig. 3.14 A).  In this way, we could assess the contribution of cDC numbers to enhanced priming 
and the overall recall response. 
Following OT-II transfer and PR8-OTII challenge, the frequency and numbers of cDC 
were significantly reduced in the medLN of DT-treated compared to untreated mice; however, 
cDC numbers in the lung were comparable in infected hosts +/- DT (Fig. 3.14 B). This medLN-
localized cDC depletion was associated with significant weight loss in DT-treated compared to the 
untreated group (Fig. 3.14 C), demonstrating a loss of memory T cell-mediated protection. The 
accumulation and proliferation of OT-II cells in the medLN was significantly reduced in DT-
treated compared to untreated mice (Fig. 3.14 D).  At the same time, OT-II cells did not proliferate 
in the spleen, demonstrating that the enhanced antigen-specific T cell priming is locally regulated 
(Fig 3.14 D).  We also tested whether cDC depletion would diminish the enhanced medLN priming 
of IAV-specific CD8+ T cell responses by transferring OT-I cells into DT treated and untreated 
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memory mice and challenging those mice with PR8-OTI.  Like OT-II cells, OT-I cells also 
exhibited significantly abrogated proliferation within the medLN (Fig. 3.14 E), suggesting that 
increased cDC numbers enhance both CD4+ and CD8+ influenza-specific T cell priming and 
proliferation.  Consistent with transgenic flu-specific T cell responses, the total number of both 
polyclonal medLN CD4+ and CD8+ T cells also significantly decreased with DT depletion (Fig. 
3.14 F).  Together, these results demonstrate that cDCs in the medLN are required for enhanced 
priming and proliferative expansion of influenza specific CD4+ and CD8+ T cells observed during 




Figure 3.14: MedLN cDC are required for enhanced T cell priming and protection during 
the recall response 
(A) Schematic for cDC depletion experiments:  B6 CD45.1+/+ mice were lethally irradiated and 
reconstituted with 107 CD45.2+/+ zbtb46-DTR bone marrow cells to create B6.zDTR bone marrow 
chimeras.  After 10 weeks, B6.zDTR chimeras were infected with X31 to generate B6.zDTR 
memory mice. B6.zDTR memory mice were treated with FTY720 and either treated with i.p. DT 
(40mg/g body weight) or PBS as a vehicle control.  One day later, mice were administered i.n. DT 
(20mg/g body weight) or PBS vehicle control and eF450 proliferation dye labeled 
CD45.1+CD45.2+ OT-I or OT-II cells were transferred into FTY720 treated B6.zDTR memory 
mice.  One day later, mice were challenged with PR8-OTI or PR8-OTII (see methods), and recall 
protection and OT-I/OT-II priming was assessed 3 days post-infection.  (B) Preferential reduction 
in medLN cDC following DT treatment in B6.zDTR memory mice depicted in representative flow 
cytometry plots (left) gated on CD45+ cells showing CD11c+ cDC in the MedLN and lungs of  
PR8-OTII challenged mice, and in graphs of cDC numbers in each site (right). Data representative 
of 2 independent experiments, n=3-4 mice/group. (C) Weight loss morbidity DT-treated and 
untreated memory mice at indicated times after PR8-OTII challenge. Data compiled from 2 
independent experiments, n=6 mice/group. (D) DT treatment abrogates enhanced priming of 
medLN OT-II cells. Left: Flow cytometry plots show medLN and spleen OT-II proliferation and 
CD69 expression with and without DT treatment.  Right: MedLN and spleen OT-II counts and 
proportion of OT-II cells that fully diluted proliferation dye.  Data are compiled from of two 
independent experiments (n=3-7 mice/group).  (E) DT treatment also abrogates enhanced priming 
of medLN OT-I cells. Left: Flow cytometry plots show medLN OT-I proliferation and CD69 
expression with and without DT treatment three days after PR8-OTI challenge.  Right: Plots 
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depicting proportion of medLN OT-I cells that express diluted levels of proliferation dye.  N=5 
mice/group.  (F) DT treatment abrogates medLN polyclonal T cell responses. Graph depicts 
absolute number of medLN CD4+ and CD8+ T cells with and without DT treatment.  Data compiled 
from 2 independent experiments, n=7 mice/group.  Significance determined by student’s unpaired 













Influenza infection generates lung TRM that can provide cross-strain protective immunity, 
though the interactions of systemic responses with lung resident immunity are not defined. Here, 
we reveal how local lung tissue T cell immunity to heterosubtypic challenge is augmented by the 
enhanced generation and lung homing of peripheral effector T cells. During secondary influenza 
challenge, increased numbers of T cells in the lung niche early after infection derive from in situ 
TRM proliferation as well as the recruitment of effector cells generated in response to newly 
encountered influenza epitopes in the medLN.  Importantly, prior influenza infection imprints the 
medLN with greater numbers of cDCs including increased proportions of the CD103+ migratory 
subset, resulting in more rapid priming of naive T cells. This lymphoid cDC-mediated priming is 
required for lung-localized protective responses. Our results indicate that the efficacious secondary 
response to respiratory infection by lung TRM is augmented by the fortified priming environment 
in the local lymphoid tissue, enabling rapid mobilization of effector T cells to the site of infection.   
 Prior influenza infection generates high frequencies of memory T cells that reside within 
the lung and local medLN that are enriched for reactivity to influenza-derived epitopes [104, 173, 
174, 182].  Lung TRM can be readily identified by their localization in the lung tissue niche that 
is inaccessible to circulation and protected by labeling with intravenously administered antibody.  
Heterosubtypic influenza challenge of memory mice led to protective responses including reduced 
weight loss morbidity and more rapid viral clearance compared to the primary response, 
independent of mature B cells, consistent with previous studies showing B cells were not required 
for memory T cell-directed protection to influenza challenge [175, 183]. This polyclonal T cell-
directed response was marked by extensive accumulation of T cells in the lung resident niche, 
consistent with TRM expansion in other tissue sites following recall challenge [129, 130].  
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However, the expanding T cells in the lung resident niche did not predominantly exhibit 
phenotypic features of TRM such as CD103 expression, contrary to findings in skin and female 
reproductive tract [129, 130].  By contrast, expanded lung T cells were largely CD103-negative 
for both CD4+ and CD8+ T cells, and derived, in part, from infiltration of effector T cells from 
local lymphoid sites. The specific and distinct anatomical features of the lung, including extensive 
vascularization of the tissue and associated lymph nodes, may influence the relative involvement 
of tissue and systemic responses, which may differ from other sites.   
 Using a tracking model that monitors the activation and proliferation of OVA-specific T 
cells, we demonstrate that the environment within the medLN of previously infected mice 
promotes superior T cell effector generation and lung migration after PR8-OTI/OTII challenge, 
including for newly encountered influenza epitopes such as OVA. These results indicate a 
broadening of the early T cell response during a recall challenge. The effect of a previously 
generated influenza-specific memory response on epitopes introduced during subsequent 
infections has been examined in mouse lymphoid tissues [184], but not for the early, lung-localized 
response that is essential for protection. How prior infection impacts a subsequent immune 
response for humoral immunity is through a phenomenon referred to as “original antigenic sin”,  
in which antibody production in the recall response favors the original antigens, resulting in a 
narrowing of the antibody repertoire over repeated pathogen exposures [185-187]. The 
amplification of new T cell responses during recall suggests that T cell immunity may be more 
robust than humoral immunity in promoting universal protection, particularly during the critical 
early period of tissue localized responses.   
 We identified that enhanced priming in the recall response occurred in local medLN that 
exhibited a fortified state, being more permissive to maintaining larger numbers of T cells and 
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increased numbers of cDCs.  Recent studies have identified components of the innate immune 
response that become altered from previous infection and exhibit enhanced responses during 
recall—a phenomenon known as “trained immunity” [188, 189]. Respiratory infection with 
adenovirus induced long-term changes in alveolar macrophages (AM), resulting in memory AM 
with superior functional responses to viral challenge [155].  Here, we describe durable alterations 
in the local medLN following influenza infection manifested by elevated numbers of T cells and 
cDC subsets after viral clearance that was not observed in distal lymph nodes. Increased 
frequencies of CD103+ cDC were localized in the fortified medLN, indicating a migratory 
phenotype [60, 190, 191] that may also play a role in further promoting both CD4+ and CD8+ T 
cell priming [192]. However, the medLN cDC in memory mice were otherwise phenotypically and 
transcriptionally similar to cDC in the medLN of naïve mice, indicating that cDC are not 
qualitatively altered by the previous infection. Our results indicate that the local LN environment 
is quantitatively fortified, enabling more efficacious priming. 
Our results demonstrating endogenous boosting properties of the local lymphoid 
environment have implications for generating protective immunity to diverse respiratory infections 
in vaccines. Protective lung TRM can be generated by diverse respiratory pathogens including 
RSV, tuberculosis, and pertussis [193-195]. Intranasal routes of immunization can also generate 
lung TRM and protective immunity to influenza and pertussis in mouse models [174, 193]. We 
propose that site-specific boosting in the respiratory tract can promote more robust responses to 
new or heterologous respiratory pathogens through targeting the local fortified LN, and thus 




Chapter 4: Local lung tissue immunoregulation during heterosubtypic influenza challenge 
 
4.1: Abstract  
Although pathogen clearance is a primary objective of the immune response, associated 
inflammatory responses may damage local tissue during influenza infection.  Increased morbidity 
and mortality caused by influenza infection is correlated with highly upregulated innate 
inflammatory responses.  We demonstrate here that lung tissue resident memory T cells (TRM) 
exhibit superior production of both antiviral Th1 and immunomodulatory cytokines compared to 
their circulating counterparts and that lung tissue APCs drive IL-10 family cytokine TRM 
production.  Using a murine heterosubtypic influenza challenge model, we found that compared 
to a primary infection, the early recall response exhibited a considerably dampened innate immune 
response, particularly in type I interferon signaling.  This dampened recall response includes 
enhanced in situ production of IL-10 by lung CD4+ T cells as compared to a primary response.  
Using an αIL-10R antibody blockade, we demonstrate that IL-10 signaling modulates 
inflammatory cytokine production in the airway without inhibiting viral clearance.  Our study 
shows that prior influenza infection generates a lung environment that, during IAV challenge, 






 Viral infections elicit protective immune responses that are necessary for viral clearance 
but may also independently exacerbate disease pathology through the action of pro-inflammatory 
cytokines and effector T cells.  Aberrantly high levels of soluble immune mediators are features 
of what is known as a “cytokine storm” which causes severe tissue pathology and multi-organ 
failure [196].  Elevated inflammatory cytokine and cellular responses are correlated with the 
increased morbidity and mortality of respiratory viruses such as influenza, RSV, and 
coronaviruses, indicating that maintaining an appropriate immune response is critical for favorable 
disease outcomes [197-202].  Anti-inflammatory treatments have shown to reduce IAV morbidity 
and mortality in animal models, suggesting that an endogenous counterbalancing 
immunoregulatory response is necessary to limit lung tissue injury [162].  Although T cells are 
critical for viral clearance, both CD4+ and CD8+ T cell inflammatory responses lead to significant 
morbidity and tissue damage [175, 203].  T-cell derived inflammatory cytokines such as TNF-α 
have been shown to cause such immunopathology, ostensibly due to increased inflammation and 
leukocyte recruitment [79, 204]. 
A counterbalancing immunoregulatory response is a feature of the overall immune 
response to influenza infection and is mediated by immune cell subsets and their secreted 
cytokines.  Dendritic cells, macrophages, B cells are known producers of immunosuppressive 
cytokines, as well as various subsets of T lymphocytes including regulatory CD4+ T cells (Treg) 
which defined by the expression of transcription factor Foxp3.  These immunoregulatory cytokines 
include TGF-β, IL-10, and amphiregulin, which limit tissue damage and mortality during IAV 
infection [205].  In particular, IL-10 is one of the most highly expressed immunomodulatory 
cytokines and acts on a broad range of immune cells including lymphocytes, macrophages, and 
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dendritic cells.  IL-10 exerts its immunosuppressive function on virtually all leukocytes by 
regulating gene transcription in a STAT3 dependent fashion and has been shown to determine viral 
clearance in animal models [206].  Additionally, IL-10 counteracts many of the proinflammatory 
signals that are induced by viral PRR activation.  While Treg cells are can produce IL-10, effector 
CD4+ and CD8+ Th1 T cells are the major sources of high levels of IL-10 during active viral 
infection in mouse models; moreover, IL-10 is necessary to minimize inflammation and disease 
severity during viral clearance [85, 207, 208]. 
We demonstrated in Chapter 3 that during a heterosubtypic response, enhanced effector T 
cell expansion and migration to lung tissue mediated heterosubtypic antiviral protection.  In this 
chapter, we investigate the immunomodulatory role of the T cell response during recall compared 
to the primary response.  We demonstrate that ex vivo lung niche CD4+ memory T cells are capable 
of superior production of both inflammatory and immunomodulatory cytokines that is dependent 
on the local tissue priming environment.  During an early recall infection, lung tissue-wide immune 
responses are transcriptionally distinct from the primary response, especially reductions of 
mediators within the type I IFN pathway.  Furthermore, lung niche CD4+ effector T cell IL-10 
production is enhanced at the site of infection as compared to a primary infection.  By blocking 
IL-10R signaling, we demonstrate that airway IL-10 regulates global local lung and airway innate 
immunity and that while IL-10 suppresses Th1 cytokine responses in the airway, it does not 
suppress IAV viral clearance nor disease morbidity.  Taken together, we present a model for the 
lung environment enhanced T cell-mediated IL-10 dependent immunomodulation during a recall 






Enhanced lung TRM cytokine production is modulated by tissue antigen-presenting cells 
 To define the cytokine profile of lung-localized recall responses, we first assessed the 
cytokine production of CD4+ lung TRM cells compared to their circulating counterparts, 
specifically splenic CD4+ TEM cells.  Lung TRM were identified by their localization in lung 
tissue niche, which is defined by a lack of fluorescent staining by an intravenously injected in vivo 
antibody, demonstrating protection from the blood circulation as previously described [104].  
CD4+ CD44hi CD62Llo T cells were sorted from both the lung niche and spleen of mice that had 
been infected with X31 virus 3 weeks previously.  These sorted memory CD4+ T cells were 
stimulated with αCD3/28 activating beads for 24 hours, and the resulting supernatant was analyzed 
for various Th1, Th2, and Th17 cytokines using a cytometric bead array.  Influenza generated 
TRM produced significantly more Th1-like cytokines IFN-ɣ and TNF-α while simultaneously 
producing more IL-10 as well.  IL-4 was also significantly elevated in the splenic cells compared 
to the lung niche, perhaps indicative of a role for B cell help that is of greater importance in a 
lymphoid site such as the spleen compared to the lung (Fig. 4.1).  These data suggest that lung 
niche memory CD4+ T cells have enhanced production of proinflammatory and immunoregulatory 
cytokines IFN-ɣ, TNF-α, and IL-10, while spleen-derived memory T cells have enhanced IL-4 
production.  These data suggest that memory T cell cytokine production is adapted to their tissue 
localization and is consistent with lung TRM being especially important for directly pro-
inflammatory antiviral responses whereas splenic T cells play a role in helping B cell 
differentiation. 
 We used OT-II CD4+ T cell TCR transgenic T cells to generate antigen-specific T cells in 
lungs and spleen so that we could analyze the cytokine response to stimulation by their cognate 
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antigen, the ovalbumin peptide OVA323-339.  In order to generate substantial numbers of OT-II lung 
TRM, we used an in vitro priming and adoptive transfer model previously used in our laboratory’s 
studies of lung CD4+ TRM [94, 175].  In this model, OT-II CD4+ T cells were stimulated in vitro 
with their cognate antigen OVA323-339 peptide, and the resultant activated/effector cells are 
transferred into RAG-/- mice which lack T lymphocytes.  After 3-4 weeks, activated OT-II cells 
establish themselves as memory T cells in various lymphoid and peripheral tissue niches, including 
the lung and spleen [94].  Unlike an influenza generated infection model, both TRM and TEM are 
generated from the same priming event, allowing for more precise interrogation of tissue 
localization’s effects on memory T cell function.  OT-II Lung TRM exhibit the same phenotypic 
markers and localization of TRM as those generated by influenza infection in wild type mice; they 
are nearly all protected from in vivo labeling antibody and are CD44hi CD62Llo and express high 
levels of CD69 (Fig. 4.2 A).   
Whole lung and spleen cells from OT-II RAG-/- memory mice were cultured while 
normalizing for the number of OT-II memory T cells together with varying concentrations of 
OVA323-339 peptide.  In response to antigenic stimulation ex vivo, OT-II lung TRM produce robust 
levels of Th1 and Th2 cytokines in a dose dependent response when co-cultured with total lung 
homogenate (Fig. 4.2 B).  Similar to polyclonal TRM generated by IAV infection (Fig. 4.1), OT-
II lung TRM also exhibit enhanced cytokine production compared to their splenic TEM 
counterparts, particularly for IFN-ɣ and IL-17A (Fig. 4.2 B).  Because OT-II cells were co-cultured 
with their respective non-lymphocyte lung or spleen cells, we wished to further investigate whether 
the cytokine production by CD4+ memory T cells was dependent on the type of antigen presenting 
cells located within the tissue environment.  Sorted lung OT-II TRM or splenic OT-II TEM were 
co-cultured with lymphocyte depleted lung or spleen cells to serve as APCs at varying 
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concentrations of OVA323-339 peptide.  Both lung and spleen memory T cells produced higher levels 
of IFN-ɣ when stimulated by spleen-derived APCs compared to lung-derived APCs (Fig. 4.2 C).  
Although lung APCs seemed to produce increased IL-17A at baseline compared to spleen APCs, 
the dose response curve itself was unchanged regardless of which APC was used, suggesting that 
the tissue source of APC was immaterial to CD4+ memory T cell IL-17A responses.  Rather, OT-
II lung TRM themselves seemed to be intrinsically superior producers of IL-17A compared to OT-
II spleen TEM, exhibiting a more responsive IL-17A production profile after peptide stimulation.  
While IL-10 production itself was uneven in this TRM model (data not shown), IL-22, which is 
another member of the IL-10 cytokine family and signals through IL-10RB, was produced in high 
concentrations in our model.  IL-22 production reached an inflexion point and began to level off 
at peptide concentrations between 1 and 10 µg/mL, unlike IFN-ɣ and IL-17A which continued to 
increase exponentially in the same peptide concentration range.  Furthermore, no intrinsic 
difference in IL-22 production capacity was found between lung TRM and spleen TEM.  Rather, 
the differences in IL-22 production was solely due the APCs in which lung APCs led to 
significantly greater IL-22 production compared to spleen APCs (Fig. 4.2 C).  These data suggest 
that while lung TRM are intrinsically robust cytokine producers of a wide range of cytokines, the 
local tissue environment itself, and in particular the APC population, may play a critical role in the 
determination of which types of cytokines are produced in situ during a respiratory infection, 





Figure 4.1: Cytokine profile of αCD3/28 bead stimulated CD4+ lung niche and splenic 
memory T cells 
CD44hi CD62Llo CD4+ cells were sorted from lung and spleen from mice 4-6 weeks post-infection.  
Lung cells were sorted from lung niche determined by in vivo labeling technique, and splenic T 
cells were in vivo label positive.  Cells were plated with 1 µL CD3/28 T-cell activator beads in a 
96 well plate in 200 µL of media at 2×104 cells/well.  After 24 hours of stimulation, supernatant 
was analyzed by cytometric bead array (BD Biosciences). N=3 mice. Data is representative of 2 
independent experiments displaying mean and SD.  Statistical significance determined by unpaired 











Figure 4.2 Tissue specificity of lung CD4+ TRM cytokine production dependent on antigen-
presenting cells type 
 (A)  OT-II cells were isolated from the lungs of in vivo labeled RAG-/- OT-II memory mice.  FACS 
plots are gated on CD4+ T cells and depict CD44 and CD62L expression (left) as well as CD69 
expression plotted against in vivo labeling (right). (B) Total lung homogenate from RAG-/- OT-II 
memory mice was cultured with various concentrations of OVA323-339
 peptide for 24 hours. 
Supernatant was measured for cytokine levels using LEGENDplex immunoassay (Biolegend).   
(C) Lung (black) and spleen (red) OT-II CD4+ memory T cells were sorted from RAG-/- OT-II 
memory mice and 2×104 cells were co-cultured with equal numbers of lung (solid) or spleen (open) 
cells from RAG-/- mice in a 96 well U-bottom plate.  Wells contained various concentrations of 
OVA323-339
 peptide, and plate was cultured at 37 ºC for 24 hours. Supernatant was measured for 
cytokines using LEGENDplex immunoassay.  Graphs depict dose response curves for IFN-ɣ (left), 































































































Lung environment undergoes globally attenuated innate immune response during 
heterosubtypic challenge 
  The results above demonstrate that the response in the lung can be influenced by intrinsic 
differences in the functional capacity of TRM as well as the APC in the lung tissue.  We therefore 
took an unbiased approach to investigate early immunomodulatory effects on the lung by 
comparing the whole lung transcriptional profiles of the recall and primary responses using 
RNASeq.  To this end, lung tissue was isolated from naïve and memory mice both at their baseline 
prior to infection and 2 days post-challenge with PR8 IAV challenge.  RNASeq analysis revealed 
that significantly more genes were differentially expressed during a primary infection (1661) 
compared to a recall infection (160), in which 70 genes were shared (Fig. 4.3 A, B).  Differentially 
expressed genes include many upregulated and downregulated genes; while both recall and 
primary infection upregulated a number of chemokines including Ccl2, Cxcl11, Cxcl10, and Cxcl9, 
primary infection also upregulated a number of innate antiviral immune genes such as Tlr9 and 
interferon signaling genes such as Ifitm3 and Irf4 (Fig. 4.3 C).   
In order to analyze these data in the context of functional pathways, we performed Gene 
Set Enrichment Analysis (GSEA) of the differentially expressed genes in primary and secondary 
infection.  Both primary and secondary infection were enriched for genes that were similarly 
upregulated in studies of DC exposure to Newcastle disease virus [209], demonstrating a  non-
specific antiviral response (Fig. 4.3 D).  While both primary and recall were enriched, the primary 
response had a larger normalized enrichment score (NES) of 3.22 compared to 2.07.  The outsized 
immune response during primary infection was reflected in its enrichment of upregulated genes 
(NES score 3.11) after DC exposure to TLR4 and TLR7 agonists which triggered Th1  responses 
[210], which is consistent with an enhanced antiviral innate immune response by ssRNA which is 
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a ligand for TLR7 [12] (Fig. 4.3 E).  Further pathway analysis using Ingenuity Pathway Analysis 
(IPA) revealed significant changes during primary infection of EIF2 mediated mRNA translation, 
metabolic pathways such as mTOR, oxidative phosphorylation, and mitochondrial function, in 
addition to interferon and leukocyte migration pathways that are upregulated in both recall and 
primary infection (Fig. 4.3 F).  These data demonstrate that the magnitude of the global 
transcriptional response is significantly larger during a primary infection, particularly with respect 
to innate immune signaling, while there are fewer innate immune-associated genes induced during 
the recall response.  Together these data suggest an immunomodulatory function inherent within 




Figure 4.3: Early recall response modulates early innate response of the total lung 
transcriptome 
Whole right lung lobes were isolated from naïve and memory mice as well as naïve and memory 
mice 2 days after challenge with PR8 influenza virus during FTY720 treatment.  Reads were 
mapped using Salmon and DESeq2 was used to determine significantly differentially expressed 
genes after a primary infection by comparing transcriptomes of uninfected and infected naïve mice, 
as well as a recall infection by comparing transcriptomes of uninfected and infected memory mice. 
(A) Venn diagram illustrating the number of differentially expressed genes in a primary infection 
versus baseline compared to a recall infection versus baseline, as well as the number of genes 
which overlap between primary and recall infection.  (B) Heat map showing the genes that are 
differentially upregulated in a primary infection compared to a secondary infection (C) Scatter plot 
illustrating plotting genes based on their differential expression in a primary (red) and recall 
response (blue), differentially expressed in both conditions (purple), or not differentially expressed 
in any condition (black).  (D) GSEA of differentially expressed preranked gene list from primary 
and recall infection compared to independently identified upregulated genes in dendritic cells after 
Newcastle viral challenge. (E) GSEA of differentially expressed preranked gene list from primary 
infection compared to independently identified upregulated genes in dendritic cells after LPS and 
R848 challenge. (F) IPA analysis depicting key differentially expressed pathways in both primary 
and recall infections.  Differential expression in all cases was determined if Padj <0.05 and with an 
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Enhanced IL-10 production by lung niche CD4+ T cells during heterosubtypic influenza 
challenge 
Given the biased production of IL-10 family cytokines by lung TRM and the overall 
dampened innate immune response in the lung, we sought to determine the extent of in situ IL-10 
production by lung niche T cells during a recall response compared to a primary response.  We 
used IL-10 GFP-reporter “Tiger” mice to detect in situ IL-10 producing T cells.  Tiger mice were 
infected with X31 IAV to generate memory, and both naïve and memory tiger mice were 
challenged with PR8 IAV, similar to previous influenza challenge models (Fig. 3.3 A).  Mice were 
also treated with FTY720 to sequester circulating cells so as to limit their contributions to the early 
tissue-localized immune response.  Five days after challenge, the lung niche CD4+ CD44hi 
CD62Llo T cell population during the recall response was significantly enriched for IL-10 
producing cells compared to the primary response (Fig. 4.4).  On the other hand, the proportion of 
lung niche CD8+ T cell IL-10 producers was unchanged between the primary and recall responses.  
In contrast to the lung, while medLN CD4+ CD44hi CD62Llo T cells did produce modest levels of 
IL-10 (~5% GFP+), we did not observe any enhancement in IL-10 production during the recall 
response (Fig. 4.4 B), which suggests that the skew toward IL-10 production did not occur within 
lymphoid sites, but rather, after T cells migrated to the lung tissue niche.   
We also observed that during the recall response, non-TRM cells were the primary 
producers of IL-10.  While CD69- and CD103- CD4+ T cells were ~30-35% GFP+, their CD69+ or 
CD103+ TRM counterparts were less than 5% GFP+ (Fig. 4.4 A).  This was also true for CD8+ T 
cells.  CD103- CD8+ T cells comprised the overwhelming majority of CD8+ T cell IL-10 
production (~10% GFP+) compared to CD103+ cells (<1% GFP+).  Taken together, these data 
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suggest that effector T cells drive enhanced recall immunomodulatory function upon their 





Figure 4.4: Enhanced lung niche CD4+ IL-10 production during recall response 
IL-10-GFP reporter “tiger” memory mice were treated with FTY720 and challenged with PR8 
virus.  Lung and medLN T cells were isolated after 5 days and analyzed by flow cytometry.  (A) 
Lung niche CD44hi CD62Llo CD4+ (left) and CD8+ (right) CD44+ T cell IL-10 expression is 
depicted on FACS plots against TRM markers CD69 (top) and CD103 (bottom).  Compiled data 
depicted (right) for IL-10 expression stratified by CD69 expression (top right) and CD103 
expression (bottom right).  (B) MedLN CD44hi CD62Llo T cell IL-10-GFP is depicted in graphs 
(right) and on FACS plots against CD69 expression (left).  N=2-3 mice per group.  Statistical 








IL-10 signaling modulates Th1 responses but preserves heterosubtypic immunity 
 The results above suggest a key role for IL-10 signaling in modulating lung-localized recall 
responses to influenza challenge.  We therefore inhibited IL-10R signaling during heterosubtypic 
challenge using αIL-10R blocking antibody just prior to and during heterosubtypic influenza 
challenge.  We observed no change in weight loss morbidity in the anti-IL-10R treated group 
compared to the vehicle control group (Fig. 4.5 A), and no difference in viral clearance was 
observed six days after challenge as well (Fig. 4.5 B).  The cytokine levels in the lung 
bronchoalveolar lavage (BAL) washes of treated animals contained elevated IL-10 (Fig. 4.5 C), 
confirming that αIL-10R antibody treatment was sufficient to block IL-10 uptake.  However, BAL 
from treated mice also contained significantly elevated levels of IFN-γ and TNF-α (Fig. 4.5 C), 
demonstrating that IL-10 signaling is necessary to modulate Th1 antiviral and inflammatory 
pathways.  These changes in cytokine production were not caused by changes in the number of T 
cells, as no significant difference in the number of CD4+ and CD8+ lung T cells was observed 
between the αIL-10R blockade and vehicle control groups (Fig. 4.5 D).  These results indicate that 
enhanced lung niche CD4+ effector T cell IL-10 signaling suppress Th1 cytokine production 




Figure 4.5: Recall response IL-10 signaling modulates Th1 responses while maintaining 
antiviral protection 
Wild type memory mice were treated with FTY720 and i.p. and i.n. αIL-10R antibody and 
challenged with PR8 virus.  (A) Weight loss as percentage of day 0 body weight compared between 
treated and vehicle control groups. (B) BAL Viral titers from αIL-10R and vehicle control treated 
mice 6 days post challenge.  (C) Graphs depicting day 6 BAL cytokine concentration as determined 
by Legendplex cytometric bead array (Biolegend). (D) Graphs depicting lung niche CD4+ (left) 
and CD8+ (right) CD44hi CD62Llo T cell counts.  All data compiled from 2 independent 
experiments depicting mean ± SEM.   N=11-12 mice. Statistical significance determined by 








Recall responses to heterosubtypic influenza challenge provide cross strain protective 
immunity, but the mechanisms by which inflammatory responses are modulated are not well 
defined.  Here, we reveal that lung CD4+ tissue resident memory T cells have a distinct cytokine 
profile compared to circulating CD4+ memory T cells that is influenced by the tissue priming 
environment.  Compared to splenic, circulating effector memory CD4+ T cells, CD4+ lung TRM 
produce more IL-10 after in vitro restimulation.  Using a heterosubtypic IAV challenge model, we 
found that early tissue-localized recall responses resulted in globally suppressed inflammatory 
pathways in the lung at the transcriptional level.  Further cellular analysis of the T cell response 
revealed that enhanced CD4+ lung effector T cell expansion as described in Chapter 3 is concurrent 
with enhanced IL-10 production which is critical to modulating inflammatory immune responses 
while preserving viral clearance.  These data demonstrate that efficacious antiviral T cell responses 
during a heterosubtypic IAV response are augmented by an immunomodulatory lung environment 
that includes IL-10 production by lung niche CD4+ effector and memory T cells. 
Lung CD4+ TRM are generated in two models of CD4+ TRM generation: a primary 
influenza infection to generate polyclonal TRM and the adoptive transfer of in vitro activated OT-
II T cells into RAG-/- lymphopenic mice to generate OT-II TCR transgenic TRM.  In both models, 
TRM are more potent cytokine producers of IFN-ɣ, TNF-α, IL-17A, and IL-10 after either 
αCD3/28 or OVA323-339 peptide stimulation as compared to their circulating splenic TEM 
counterparts.  Furthermore, we found that the peptide dose response curves of TRM cytokine 
production were affected by the type of tissue cells used to present antigen; IL-22 production was 
solely dependent on the use of lung APCs compared to splenic APCs, suggesting that the lung 
environment itself may have an outsized impact on the production of IL-10 family cytokines.  
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However, when considering the context of continual environmental exposure, the lung contains 
unique microbiota that may alter lung T cell responses or contribute to the differential cytokine 
production when co-cultured with T cells [211], and the lung microbiota may be particularly 
altered in lymphopenic RAG-/- mice which are the experimental source of tissue APCs.  The lung’s 
heterogenous APC population also includes a range of dendritic cells, alveolar macrophages, and 
interstitial macrophages which may promote more variable cytokine responses compared to 
lymphoid APCs that promote Th1 cytokines more important in priming and proliferation in 
response to viral antigens. 
By analyzing the transcriptional changes of total lung tissue during primary and recall 
responses to influenza, we determined that the primary response induces significantly more 
transcriptional changes, including in innate immune signaling pathways such as interferon 
signaling, protein translation, and cellular metabolism.  These data suggest that after recovery from 
a primary infection, the lung environment is fundamentally altered to modulate lung niche effector 
T cell function, which is supported by our finding that effector CD4+ T cells during a recall 
response produce significantly more IL-10 compared to a primary infection.  MedLN CD4+ T cells 
produce low levels of IL-10 without any difference between primary and secondary infection, 
suggesting that shift toward IL-10 production is induced by the lung environment.  These results 
support previous observations that lung CD4+ T cells have been shown to be predisposed toward 
immunomodulatory function compared to systemic CD4+ T cells [212].  However, we observe 
tissue-wide transcriptional immunoregulation (2 days post challenge) well before the rapid influx 
of CD4+ T cells (5 days post challenge) even though there are significantly fewer IL-10 producing 
TRM than non-TRM.  We postulate that even though CD4+ and CD8+ TRM produce less IL-10, 
compared to effector CD4+ T cells, TRM are present in large enough numbers where even modest 
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IL-10 production in the early stages of infection is sufficient to produce the observed 
immunomodulatory effects.  We further demonstrated with a blockade of enhanced IL-10 signaling 
that IL-10 suppresses inflammatory IFN-ɣ and TNF-α cytokine levels in the airways without 
affecting viral clearance during a heterosubtypic IAV infection.   
  Our findings demonstrate that the resolution of primary influenza infection leads to 
increased immunoregulation in the lung environment that enhances CD4+ T cell IL-10 production 
during subsequent viral exposures, which has implications for respiratory antiviral therapies that 
may seek to reduce excess tissue inflammation and cytokine storms, as well as vaccines which 
may benefit from site specific delivery methods to induce the immunoregulatory features of local 
tissue memory generated by a primary infection.   
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Chapter 5: Conclusions 
Defining the features of lung localized T cell immunity that contribute to enhanced cross-strain 
protection against IAV 
Current vaccination strategies that target antibody generation have proven insufficient in 
generating long-lasting, efficacious protection against seasonal strains of influenza A virus (IAV).  
On the other hand, T cells react against a wider range of highly conserved influenza epitopes, 
offering cross-strain protection [166].  A significant body of evidence over the past decade has 
identified tissue resident memory T cells (TRM) as important mediators of antiviral immunity; 
TRM localize to a wide variety of tissues such as the in the lung and airways and mediate tissue-
localized immune responses against influenza virus (IAV) infection [94, 119, 120, 125].  
Understanding the protective mechanisms tissue resident T cell responses will provide insight into 
immunization strategies that optimize cross-strain immunity and a universal IAV vaccine.   
We used a primary H3N2 IAV infection with the X31 strain in order to generate protective, 
cross-strain immunity against an H1N1 heterosubtypic IAV challenge with the PR8 strain.  
Memory responses were protective even in B cell-deficient µMT mice as well as in the presence 
of FTY720 treatment which minimizes peripheral T cell migration, suggesting that a primary 
infection confers tissue-localized T cell-based immunity.  By studying the lung niche T cell in both 
previously infected and uninfected mice, we identified enhancements in T cell expansion during 
the recall response.  While recent TRM studies of the skin and reproductive tract found TRM 
proliferation to dominate in situ T cell responses [129, 130], our results suggest non-TRM 
comprised a majority of lung niche T cell expansion during secondary infection and also 
proliferated in situ.  Despite the use of FTY720, the possibility also remained that peripheral T 
cells might also enter the lung niche to further contribute to non-TRM T cell expansion.  
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By identifying newly generated effector T cells in the lung niche, we could reasonably 
suppose that those cells must migrate from the periphery, given that the lung is not a recognized 
site of naïve T cell priming.  We transferred naïve OT-II cells and observed that during infection 
with PR8-OTII, CD4+ OT-II effector T cells migrated to the lung more quickly during a recall 
response than a primary response, suggesting that increased peripheral T cell migration must be a 
mechanism for lung T cell expansion.  Interestingly, our results showed that the early recall 
response resulted in a broadening of the T cell repertoire by including newly generated effector T 
cells against novel IAV epitopes in addition to the reactivation of previously generated cross-
reactive memory T cells.   
Another benefit of our experimental strategy was that we could also compare the responses 
of our common transgenic T cell indicator population between a primary and recall response, 
allowing us to conclude that any differences in the T cell response were due to the local tissue 
immune environment rather than the T cells themselves.  By analyzing both OT-I and OT-II 
responses to their respective recombinant PR8-OVA viruses, we observed significant 
enhancements in CD4+ and CD8+ T cell priming and proliferation in the mediastinal lymph node 
(medLN) that underly the rapid migration to the lung niche during a recall response.   At steady 
state, medLN of memory mice retained significantly more total T cells and CD103+ migratory and 
CD11b+ LN resident zbtb46+ conventional dendritic cells (cDCs).  We created bone marrow 
chimera mice using donor cells expressing diphtheria toxin receptor (DTR) under the promoter of 
the cDC-specific Zbtb46 transcription factor.  Enhanced T cell proliferation of OT-I and OT-II in 
chimeric memory mice was abrogated by medLN cDC depletion after diphtheria toxin treatment, 
demonstrating that increased numbers of cDCs are the underlying mechanism for enhanced CD4+ 
and CD8+ T cell priming and proliferation during a recall response.  
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We propose a model for T-cell mediated heterosubtypic immunity in which prior influenza 
exposure induces durable fortification of local draining lymph nodes with increased numbers of 
both CD103+ and CD11b+ cDCs that provide increased antigen presentation (Figure 5.1).   Upon 
exposure to a new strain of IAV, lung dendritic cells transport antigen to the medLN where they 
can share antigen [58] with the increased number of cDCs which activate both pre-existing 
memory and naïve T cells to mount a rapid and broadened effector T cell response that migrates 
to the lung resident niche to augment TRM responses.  Our results indicate that inoculation at the 
tissue site may fortify innate immunity in local lymphoid sites to provide enhanced T cell responses 
in addition to the generation of TRM.    
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Figure 5.1: Proposed model of lung-localized T cell immune responses to heterosubtypic 
IAV challenge 
We propose a model for tissue-localized lung T cell mediated protection against heterosubtypic 
IAV challenge.  (A) The lung localized recall response to IAV challenge is characterized by an 
increased number of pre-existing medLN conventional dendritic cells that provide enhanced 
antigen presentation to lymph node T cells, including naïve T cells.  Enhanced medLN CD4+ and 
CD8+ T cell priming results in the enhanced numbers of T cells that migrate to the lung tissue to 
augment local TRM responses.  Both TRM and effector T cells proliferate within the lung 
resident niche and provide effector function to clear IAV infection.  (B) During primary 
infection, the medLN contains fewer cDCs and T cells, leading to a more delayed migration of 
fewer T cells to the lung resident niche.  This leads to less effective viral clearance compared to 
















Immunomodulatory function of lung localized T cell immunity during heterosubtypic IAV 
infection 
 Inflammatory immune responses to respiratory infection are critical to host survival and 
tissue homeostasis.  However, these same inflammatory processes cause non-specific 
immunopathology that may result in as much morbidity as the infectious disease process itself.  
Clinical outcomes from respiratory viruses such as coronaviruses and influenza viruses are 
strongly associated with immunopathology [196-199].  Aberrantly high levels of inflammatory 
soluble mediators, known as a cytokine storm, mediate the development of immunopathology 
and are produced by both innate and adaptive T cell responses.  During an IAV infection, 
circulating memory CD4+ T cell responses play a critical role in viral clearance and immunity 
but also have been shown to increase weight loss morbidity [175].  At the same time, lung 
effector CD4+ T cells have also been shown to produce the immunomodulatory cytokine IL-10 
during IAV infection, suggesting that T cells have self-limiting mechanisms to limit 
immunopathology [85].  Yet, the role of lung-localized T cell-mediated immunomodulation 
during a memory response has not been well studied. 
 In this study we sought to assess the immunomodulatory responses of lung-localized 
CD4+ T cells during a recall response to IAV challenge.  We initially began by determining the 
cytokine production capacity of lung TRM after in vitro reactivation.  We found that memory T 
cells produce cytokines most suitable for their tissue localization.  Polyclonal lung CD4+ TRM 
generated after a primary IAV infection produced significantly more IFN-ɣ, TNF-α, and IL-10 
compared to spleen TEM, reflecting enhanced effector function of TRM that may be exposed to 
future IAV infections.  Spleen CD4+ TEM produce greater levels of IL-4, indicative of their role 
for B cell help within lymphoid sites.  We also used a model of memory T cell generation in 
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which in vitro stimulated CD4+ OT-II cells were transferred into RAG1-/- mice to produce 
antigen-specific lung OT-II TRM and spleen OT-II TEM.  Peptide stimulation of lung and spleen 
OT-II cells indicated that lung TRM are robust producers of Th1 and Th17 cytokines as well as 
IL-10 family cytokine IL-22.  Furthermore, T cell cytokine production was strongly influenced 
by the tissue localization of the antigen presenting cells; lung APCs induced increased IL-22 
production, suggesting that the lung environment drives enhanced IL-10 family cytokine 
signaling.    
 We then sought to better assess the tissue-wide effects of the recall response driven 
immunomodulation.  We analyzed transcriptional changes in the whole lung after IAV challenge 
for both a primary and secondary infection.  In a primary infection, significantly more genes 
were upregulated, including those for innate immune programs such as type I IFN signaling.  
GSEA analysis revealed significant enrichment for innate antiviral responses such as TLR3 and 
TLR7 signaling.  Given the enhanced T cell responses in a recall response demonstrated in 
Chapter 3, this paradoxical suppression of transcriptional changes suggest that lung tissue 
homeostasis is optimally regulated during a recall response.    
 With the knowledge that the lung environment is highly immunomodulatory, we used IL-
10-GFP reporter mice in a heterosubtypic influenza challenge model to assess in situ IL-10 
production in the lung niche.  While CD4+ and CD8+ T cells expressed low levels of IL-10 in the 
medLN, we observed no difference between a primary and recall response.  However, in the 
lung, CD4+ T cells produced high levels of IL-10 (>25% GFP+) in a recall response and at 
significantly greater levels compared to a primary response (<5% GFP+).  CD8+ T cells also 
produced IL-10, but we observed no difference between a recall and primary response, 
suggesting that CD4+ T cells are the main drivers of IL-10 mediated immunomodulation in a 
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memory response.  By blocking IL-10R signaling in a recall response, we show that IL-10 
signaling dampens production of inflammatory cytokines in the airway such as IFN-ɣ and TNF-
α.   
 In the context of an increased lung cellular response by Th1 polarized T cells (Chapter 3), 
the body must limit immunopathology during a memory response to IAV.  Here we demonstrate 
using in vitro models that the lung environment predisposes T cells toward immunomodulatory 
features.  This immunomodulation limits inflammatory innate responses that is mediated by IL-
10 production by lung T cells, particularly CD4+ T cells, without compromising antiviral 
function.  These results suggest that the enhanced influx of lung T cells may provide a source of 
IL-10 mediated modulation that limits immunopathology while simultaneously providing 







1. Bouvier, N.M. and P. Palese, The biology of influenza viruses. Vaccine, 2008. 26 Suppl 
4(Suppl 4): p. D49-D53. 
2. Caini, S., et al., The epidemiological signature of influenza B virus and its B/Victoria and 
B/Yamagata lineages in the 21st century. PloS one, 2019. 14(9): p. e0222381-e0222381. 
3. Iwasaki, A. and P.S. Pillai, Innate immunity to influenza virus infection. Nature reviews. 
Immunology, 2014. 14(5): p. 315-328. 
4. Hufford, M.M., et al., The effector T cell response to influenza infection. Curr Top 
Microbiol Immunol, 2015. 386: p. 423-55. 
5. Krammer, F., et al., Influenza. Nature Reviews Disease Primers, 2018. 4(1): p. 3. 
6. Trifonov, V., H. Khiabanian, and R. Rabadan, Geographic dependence, surveillance, and 
origins of the 2009 influenza A (H1N1) virus. N Engl J Med, 2009. 361(2): p. 115-9. 
7. Turrell, L., et al., The role and assembly mechanism of nucleoprotein in influenza A virus 
ribonucleoprotein complexes. Nature Communications, 2013. 4(1): p. 1591. 
8. Matrosovich, M.N., et al., Avian influenza A viruses differ from human viruses by 
recognition of sialyloligosaccharides and gangliosides and by a higher conservation of 
the HA receptor-binding site. Virology, 1997. 233(1): p. 224-34. 
9. Gomez-Puertas, P., et al., Influenza virus matrix protein is the major driving force in 
virus budding. J Virol, 2000. 74(24): p. 11538-47. 
10. Rossman, J.S. and R.A. Lamb, Influenza virus assembly and budding. Virology, 2011. 
411(2): p. 229-236. 
11. Tecle, T., S. Tripathi, and K.L. Hartshorn, Review: Defensins and cathelicidins in lung 
immunity. Innate Immun, 2010. 16(3): p. 151-9. 
12. Diebold, S.S., et al., Innate antiviral responses by means of TLR7-mediated recognition 
of single-stranded RNA. Science, 2004. 303(5663): p. 1529-31. 
13. Guillot, L., et al., Involvement of toll-like receptor 3 in the immune response of lung 
epithelial cells to double-stranded RNA and influenza A virus. J Biol Chem, 2005. 
280(7): p. 5571-80. 
14. Pichlmair, A., et al., RIG-I-mediated antiviral responses to single-stranded RNA bearing 
5'-phosphates. Science, 2006. 314(5801): p. 997-1001. 
15. Kato, H., et al., Differential roles of MDA5 and RIG-I helicases in the recognition of RNA 
viruses. Nature, 2006. 441(7089): p. 101-105. 
16. Seo, S.U., et al., MyD88 signaling is indispensable for primary influenza A virus 
infection but dispensable for secondary infection. J Virol, 2010. 84(24): p. 12713-22. 
17. Der, S.D., et al., Identification of genes differentially regulated by interferon α, β, or γ 
using oligonucleotide arrays. Proceedings of the National Academy of Sciences, 1998. 
95(26): p. 15623-15628. 
18. Chakrabarti, A., B.K. Jha, and R.H. Silverman, New Insights into the Role of RNase L in 
Innate Immunity. Journal of Interferon & Cytokine Research, 2010. 31(1): p. 49-57. 
19. Pindel, A. and A. Sadler, The Role of Protein Kinase R in the Interferon Response. 
Journal of Interferon & Cytokine Research, 2010. 31(1): p. 59-70. 
133 
 
20. Wang, X., E.R. Hinson, and P. Cresswell, The interferon-inducible protein viperin 
inhibits influenza virus release by perturbing lipid rafts. Cell Host Microbe, 2007. 2(2): 
p. 96-105. 
21. Brass, A.L., et al., The IFITM proteins mediate cellular resistance to influenza A H1N1 
virus, West Nile virus, and dengue virus. Cell, 2009. 139(7): p. 1243-54. 
22. Mordstein, M., et al., Lambda Interferon Renders Epithelial Cells of the Respiratory and 
Gastrointestinal Tracts Resistant to Viral Infections. Journal of Virology, 2010. 84(11): 
p. 5670-5677. 
23. Garcia-Sastre, A., Induction and evasion of type I interferon responses by influenza 
viruses. Virus Res, 2011. 162(1-2): p. 12-8. 
24. Allen, I.C., et al., The NLRP3 inflammasome mediates in vivo innate immunity to 
influenza A virus through recognition of viral RNA. Immunity, 2009. 30(4): p. 556-65. 
25. Thomas, P.G., et al., The intracellular sensor NLRP3 mediates key innate and healing 
responses to influenza A virus via the regulation of caspase-1. Immunity, 2009. 30(4): p. 
566-75. 
26. García-Ramírez, R.A., et al., TNF, IL6, and IL1B Polymorphisms Are Associated with 
Severe Influenza A (H1N1) Virus Infection in the Mexican Population. PLOS ONE, 2015. 
10(12): p. e0144832. 
27. Dienz, O., et al., Essential role of IL-6 in protection against H1N1 influenza virus by 
promoting neutrophil survival in the lung. Mucosal Immunology, 2012. 5(3): p. 258-266. 
28. Seo, S.H. and R.G. Webster, Tumor Necrosis Factor Alpha Exerts Powerful Anti-
Influenza Virus Effects in Lung Epithelial Cells. Journal of Virology, 2002. 76(3): p. 
1071-1076. 
29. Chan, M.C., et al., Proinflammatory cytokine responses induced by influenza A (H5N1) 
viruses in primary human alveolar and bronchial epithelial cells. Respir Res, 2005. 6: p. 
135. 
30. Fujisawa, H., Neutrophils Play an Essential Role in Cooperation with Antibody in both 
Protection against and Recovery from Pulmonary Infection with Influenza Virus in Mice. 
Journal of Virology, 2008. 82(6): p. 2772-2783. 
31. Gazit, R., et al., Lethal influenza infection in the absence of the natural killer cell 
receptor gene Ncr1. Nature Immunology, 2006. 7(5): p. 517-523. 
32. Amulic, B., et al., Neutrophil Function: From Mechanisms to Disease. Annual Review of 
Immunology, 2012. 30(1): p. 459-489. 
33. Hufford, M.M., et al., Influenza-infected neutrophils within the infected lungs act as 
antigen presenting cells for anti-viral CD8(+) T cells. PloS one, 2012. 7(10): p. e46581-
e46581. 
34. Bourdi, M., et al., Protection against acetaminophen-induced liver injury and lethality by 
interleukin 10: role of inducible nitric oxide synthase. Hepatology, 2002. 35(2): p. 289-
98. 
35. Morhardt, T.L., et al., IL-10 produced by macrophages regulates epithelial integrity in 
the small intestine. Scientific Reports, 2019. 9(1): p. 1223. 
36. Quiros, M., et al., Macrophage-derived IL-10 mediates mucosal repair by epithelial 
WISP-1 signaling. J Clin Invest, 2017. 127(9): p. 3510-3520. 
37. Sabatel, C., et al., Exposure to Bacterial CpG DNA Protects from Airway Allergic 
Inflammation by Expanding Regulatory Lung Interstitial Macrophages. Immunity, 2017. 
46(3): p. 457-473. 
134 
 
38. Bedoret, D., et al., Lung interstitial macrophages alter dendritic cell functions to prevent 
airway allergy in mice. The Journal of clinical investigation, 2009. 119(12): p. 3723-
3738. 
39. Grabiec, A.M. and T. Hussell, The role of airway macrophages in apoptotic cell 
clearance following acute and chronic lung inflammation. Seminars in 
immunopathology, 2016. 38(4): p. 409-423. 
40. Simpson, J.L., et al., Impaired macrophage phagocytosis in non-eosinophilic asthma. 
Clin Exp Allergy, 2013. 43(1): p. 29-35. 
41. Fitzpatrick, A.M., et al., Alveolar macrophage phagocytosis is impaired in children with 
poorly controlled asthma. J Allergy Clin Immunol, 2008. 121(6): p. 1372-8, 1378.e1-3. 
42. Hodge, S., et al., Alveolar macrophages from subjects with chronic obstructive 
pulmonary disease are deficient in their ability to phagocytose apoptotic airway 
epithelial cells. Immunol Cell Biol, 2003. 81(4): p. 289-96. 
43. Morimoto, K., W.J. Janssen, and M. Terada, Defective efferocytosis by alveolar 
macrophages in IPF patients. Respir Med, 2012. 106(12): p. 1800-3. 
44. Liu, K., et al., In vivo analysis of dendritic cell development and homeostasis. Science 
(New York, N.Y.), 2009. 324(5925): p. 392-397. 
45. Reizis, B., Plasmacytoid Dendritic Cells: Development, Regulation, and Function. 
Immunity, 2019. 50(1): p. 37-50. 
46. Lund , J., et al., Toll-like Receptor 9–mediated Recognition of Herpes Simplex Virus-2 by 
Plasmacytoid Dendritic Cells. Journal of Experimental Medicine, 2003. 198(3): p. 513-
520. 
47. Siegal, F.P., et al., The Nature of the Principal Type 1 Interferon-Producing Cells in 
Human Blood. 1999. 284(5421): p. 1835-1837. 
48. Cella, M., et al., Plasmacytoid monocytes migrate to inflamed lymph nodes and produce 
large amounts of type I interferon. Nature Medicine, 1999. 5(8): p. 919-923. 
49. Stout-Delgado, H.W., et al., Aging impairs IFN regulatory factor 7 up-regulation in 
plasmacytoid dendritic cells during TLR9 activation. J Immunol, 2008. 181(10): p. 6747-
56. 
50. Wolf, A.I., et al., Plasmacytoid Dendritic Cells Are Dispensable during Primary 
Influenza Virus Infection. The Journal of Immunology, 2009. 182(2): p. 871. 
51. Kim, T.S. and T.J. Braciale, Respiratory Dendritic Cell Subsets Differ in Their Capacity 
to Support the Induction of Virus-Specific Cytotoxic CD8+ T Cell Responses. PLOS 
ONE, 2009. 4(1): p. e4204. 
52. Beaty, S.R., C.E. Rose, and S.-s.J. Sung, Diverse and Potent Chemokine Production by 
Lung CD11b<sup>high</sup> Dendritic Cells in Homeostasis and in Allergic Lung 
Inflammation. The Journal of Immunology, 2007. 178(3): p. 1882-1895. 
53. Norbury, C.C., Drinking a lot is good for dendritic cells. Immunology, 2006. 117(4): p. 
443-451. 
54. Platt, C.D., et al., Mature dendritic cells use endocytic receptors to capture and present 
antigens. 2010. 107(9): p. 4287-4292. 
55. Albert, M.L., B. Sauter, and N. Bhardwaj, Dendritic cells acquire antigen from apoptotic 
cells and induce class I-restricted CTLs. Nature, 1998. 392(6671): p. 86-89. 
56. Diebold, S.S., et al., Viral infection switches non-plasmacytoid dendritic cells into high 
interferon producers. Nature, 2003. 424(6946): p. 324-8. 
135 
 
57. Smed-Sorensen, A., et al., Influenza A virus infection of human primary dendritic cells 
impairs their ability to cross-present antigen to CD8 T cells. PLoS Pathog, 2012. 8(3): p. 
e1002572. 
58. Gurevich, I., et al., Active dissemination of cellular antigens by DCs facilitates CD8(+) 
T-cell priming in lymph nodes. Eur J Immunol, 2017. 47(10): p. 1802-1818. 
59. Palm, N.W. and R. Medzhitov, Pattern recognition receptors and control of adaptive 
immunity. Immunol Rev, 2009. 227(1): p. 221-33. 
60. Ho, A.W., et al., Lung CD103+ dendritic cells efficiently transport influenza virus to the 
lymph node and load viral antigen onto MHC class I for presentation to CD8 T cells. J 
Immunol, 2011. 187(11): p. 6011-21. 
61. Russo, E., et al., Intralymphatic CCL21 Promotes Tissue Egress of Dendritic Cells 
through Afferent Lymphatic Vessels. Cell Rep, 2016. 14(7): p. 1723-1734. 
62. Ulvmar, M.H., et al., The atypical chemokine receptor CCRL1 shapes functional CCL21 
gradients in lymph nodes. Nat Immunol, 2014. 15(7): p. 623-30. 
63. GeurtsvanKessel, C.H., et al., Clearance of influenza virus from the lung depends on 
migratory langerin+CD11b- but not plasmacytoid dendritic cells. J Exp Med, 2008. 
205(7): p. 1621-34. 
64. Smith, W.A., CH; Laidlaw PP, A virus obtained from Influenza patients. The Lancet, 
1933. 222(5732): p. 66-68. 
65. Lewnard, J.A. and S. Cobey, Immune History and Influenza Vaccine Effectiveness. 
Vaccines (Basel), 2018. 6(2). 
66. Krammer, F., The human antibody response to influenza A virus infection and 
vaccination. Nature Reviews Immunology, 2019. 19(6): p. 383-397. 
67. Graham, M.B. and T.J. Braciale, Resistance to and recovery from lethal influenza virus 
infection in B lymphocyte-deficient mice. The Journal of experimental medicine, 1997. 
186(12): p. 2063-2068. 
68. Bui, H.-H., et al., Ab and T cell epitopes of influenza A virus, knowledge and 
opportunities. Proceedings of the National Academy of Sciences of the United States of 
America, 2007. 104(1): p. 246-251. 
69. Schwab, S.R. and J.G. Cyster, Finding a way out: lymphocyte egress from lymphoid 
organs. Nature Immunology, 2007. 8(12): p. 1295-1301. 
70. Lian, J. and A.D. Luster, Chemokine-guided cell positioning in the lymph node 
orchestrates the generation of adaptive immune responses. Current opinion in cell 
biology, 2015. 36: p. 1-6. 
71. Grigorova, I.L., et al., Cortical sinus probing, S1P1-dependent entry and flow-based 
capture of egressing T cells. Nat Immunol, 2009. 10(1): p. 58-65. 
72. Shiow, L.R., et al., CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and 
lymphocyte egress from lymphoid organs. Nature, 2006. 440(7083): p. 540-4. 
73. Mandala, S., et al., Alteration of lymphocyte trafficking by sphingosine-1-phosphate 
receptor agonists. Science, 2002. 296(5566): p. 346-9. 
74. Mueller, D.L., M.K. Jenkins, and R.H. Schwartz, Clonal expansion versus functional 
clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell 
antigen receptor occupancy. Annu Rev Immunol, 1989. 7: p. 445-80. 
75. Chen, L. and D.B. Flies, Molecular mechanisms of T cell co-stimulation and co-
inhibition. Nat Rev Immunol, 2013. 13(4): p. 227-42. 
136 
 
76. Boomer, J.S. and J.M. Green, An enigmatic tail of CD28 signaling. Cold Spring Harb 
Perspect Biol, 2010. 2(8): p. a002436. 
77. Kapsenberg, M.L., Dendritic-cell control of pathogen-driven T-cell polarization. Nature 
Reviews Immunology, 2003. 3(12): p. 984-993. 
78. Mikhak, Z., J.P. Strassner, and A.D. Luster, Lung dendritic cells imprint T cell lung 
homing and promote lung immunity through the chemokine receptor CCR4. J Exp Med, 
2013. 210(9): p. 1855-69. 
79. Hussell, T., A. Pennycook, and P.J. Openshaw, Inhibition of tumor necrosis factor 
reduces the severity of virus-specific lung immunopathology. Eur J Immunol, 2001. 
31(9): p. 2566-73. 
80. Cook, D.N., The role of MIP-1 alpha in inflammation and hematopoiesis. J Leukoc Biol, 
1996. 59(1): p. 61-6. 
81. Topham, D.J. and P.C. Doherty, Clearance of an Influenza A Virus by 
CD4<sup>+</sup> T Cells Is Inefficient in the Absence of B Cells. Journal of Virology, 
1998. 72(1): p. 882-885. 
82. Boyden, A.W., et al., Primary and long-term B-cell responses in the upper airway and 
lung after influenza A virus infection. Immunol Res, 2014. 59(1-3): p. 73-80. 
83. Bender, B.S., et al., Transgenic mice lacking class I major histocompatibility complex-
restricted T cells have delayed viral clearance and increased mortality after influenza 
virus challenge. J Exp Med, 1992. 175(4): p. 1143-5. 
84. Belz, G.T., et al., Compromised influenza virus-specific CD8(+)-T-cell memory in 
CD4(+)-T-cell-deficient mice. J Virol, 2002. 76(23): p. 12388-93. 
85. Sun, J., et al., Effector T cells control lung inflammation during acute influenza virus 
infection by producing IL-10. Nat Med, 2009. 15(3): p. 277-84. 
86. Vos, Q., L.A. Jones, and A.M. Kruisbeek, Mice deprived of exogenous antigenic 
stimulation develop a normal repertoire of functional T cells. J Immunol, 1992. 149(4): 
p. 1204-10. 
87. Hengel, R.L., et al., Cutting edge: L-selectin (CD62L) expression distinguishes small 
resting memory CD4+ T cells that preferentially respond to recall antigen. J Immunol, 
2003. 170(1): p. 28-32. 
88. Sallusto, F., et al., Two subsets of memory T lymphocytes with distinct homing potentials 
and effector functions. Nature, 1999. 401(6754): p. 708-712. 
89. Sathaliyawala, T., et al., Distribution and compartmentalization of human circulating and 
tissue-resident memory T cell subsets. Immunity, 2013. 38(1): p. 187-97. 
90. Thome, J.J., et al., Spatial map of human T cell compartmentalization and maintenance 
over decades of life. Cell, 2014. 159(4): p. 814-28. 
91. Steinert, E.M., et al., Quantifying Memory CD8 T Cells Reveals Regionalization of 
Immunosurveillance. Cell, 2015. 161(4): p. 737-49. 
92. Zhu, J., et al., Immune surveillance by CD8alphaalpha+ skin-resident T cells in human 
herpes virus infection. Nature, 2013. 497(7450): p. 494-7. 
93. Watanabe, R., et al., Human skin is protected by four functionally and phenotypically 
discrete populations of resident and recirculating memory T cells. Sci Transl Med, 2015. 
7(279): p. 279ra39. 
94. Teijaro, J.R., et al., Cutting edge: Tissue-retentive lung memory CD4 T cells mediate 
optimal protection to respiratory virus infection. J Immunol, 2011. 187(11): p. 5510-4. 
137 
 
95. Weisberg, S.P., et al., Tissue-Resident Memory T Cells Mediate Immune Homeostasis in 
the Human Pancreas through the PD-1/PD-L1 Pathway. Cell Rep, 2019. 29(12): p. 
3916-3932.e5. 
96. McNamara, H.A., et al., Up-regulation of LFA-1 allows liver-resident memory T cells to 
patrol and remain in the hepatic sinusoids. Sci Immunol, 2017. 2(9). 
97. Mackay, L.K., et al., Hobit and Blimp1 instruct a universal transcriptional program of 
tissue residency in lymphocytes. Science, 2016. 352(6284): p. 459-63. 
98. Sheridan, B.S., et al., Oral infection drives a distinct population of intestinal resident 
memory CD8(+) T cells with enhanced protective function. Immunity, 2014. 40(5): p. 
747-57. 
99. Beura, L.K., et al., T Cells in Nonlymphoid Tissues Give Rise to Lymph-Node-Resident 
Memory T Cells. Immunity, 2018. 48(2): p. 327-338 e5. 
100. Zens, K.D., J.K. Chen, and D.L. Farber, Vaccine-generated lung tissue-resident memory 
T cells provide heterosubtypic protection to influenza infection. JCI Insight, 2016. 1(10). 
101. Kumar, B.V., et al., Human Tissue-Resident Memory T Cells Are Defined by Core 
Transcriptional and Functional Signatures in Lymphoid and Mucosal Sites. Cell Rep, 
2017. 20(12): p. 2921-2934. 
102. Wakim, L.M., et al., The molecular signature of tissue resident memory CD8 T cells 
isolated from the brain. J Immunol, 2012. 189(7): p. 3462-71. 
103. Anderson, K.G., et al., Cutting edge: intravascular staining redefines lung CD8 T cell 
responses. J Immunol, 2012. 189(6): p. 2702-6. 
104. Turner, D.L., et al., Lung niches for the generation and maintenance of tissue-resident 
memory T cells. Mucosal Immunol, 2014. 7(3): p. 501-10. 
105. Gebhardt, T., et al., Memory T cells in nonlymphoid tissue that provide enhanced local 
immunity during infection with herpes simplex virus. Nat Immunol, 2009. 10(5): p. 524-
30. 
106. Snyder, M.E., et al., Generation and persistence of human tissue-resident memory T cells 
in lung transplantation. Sci Immunol, 2019. 4(33). 
107. Mani, V., et al., Migratory DCs activate TGF-beta to precondition naive CD8(+) T cells 
for tissue-resident memory fate. Science, 2019. 366(6462). 
108. Hirai, T., et al., Keratinocyte-Mediated Activation of the Cytokine TGF-beta Maintains 
Skin Recirculating Memory CD8(+) T Cells. Immunity, 2019. 50(5): p. 1249-1261.e5. 
109. Wein, A.N., et al., CXCR6 regulates localization of tissue-resident memory CD8 T cells 
to the airways. J Exp Med, 2019. 216(12): p. 2748-2762. 
110. Takamura, S., et al., Interstitial-resident memory CD8+ T cells sustain frontline 
epithelial memory in the lung. Journal of Experimental Medicine, 2019. 216(12): p. 2736-
2747. 
111. Slutter, B., et al., Dynamics of influenza-induced lung-resident memory T cells underlie 
waning heterosubtypic immunity. Sci Immunol, 2017. 2(7). 
112. Hayward, S.L., et al., Environmental cues regulate epigenetic reprogramming of airway-
resident memory CD8(+) T cells. Nat Immunol, 2020. 21(3): p. 309-320. 
113. Van Braeckel-Budimir, N., et al., Repeated Antigen Exposure Extends the Durability of 
Influenza-Specific Lung-Resident Memory CD8(+) T Cells and Heterosubtypic Immunity. 
Cell Rep, 2018. 24(13): p. 3374-3382 e3. 
138 
 
114. Turner, D.L., et al., Biased Generation and In Situ Activation of Lung Tissue-Resident 
Memory CD4 T Cells in the Pathogenesis of Allergic Asthma. J Immunol, 2018. 200(5): 
p. 1561-1569. 
115. Amezcua Vesely, M.C., et al., Effector T(H)17 Cells Give Rise to Long-Lived T(RM) 
Cells that Are Essential for an Immediate Response against Bacterial Infection. Cell, 
2019. 178(5): p. 1176-1188.e15. 
116. Iijima, N. and A. Iwasaki, T cell memory. A local macrophage chemokine network 
sustains protective tissue-resident memory CD4 T cells. Science, 2014. 346(6205): p. 93-
8. 
117. Takamura, S., Niches for the Long-Term Maintenance of Tissue-Resident Memory T 
Cells. Front Immunol, 2018. 9: p. 1214. 
118. Zheng, X., et al., Mucosal CD8+ T cell responses induced by an MCMV based vaccine 
vector confer protection against influenza challenge. PLOS Pathogens, 2019. 15(9): p. 
e1008036. 
119. McMaster, S.R., et al., Airway-Resident Memory CD8 T Cells Provide Antigen-Specific 
Protection against Respiratory Virus Challenge through Rapid IFN-gamma Production. J 
Immunol, 2015. 195(1): p. 203-9. 
120. Mackay, L.K., et al., Long-lived epithelial immunity by tissue-resident memory T (TRM) 
cells in the absence of persisting local antigen presentation. Proc Natl Acad Sci U S A, 
2012. 109(18): p. 7037-42. 
121. Srivastava, R., et al., CXCL17 Chemokine-Dependent Mobilization of CXCR8(+)CD8(+) 
Effector Memory and Tissue-Resident Memory T Cells in the Vaginal Mucosa Is 
Associated with Protection against Genital Herpes. J Immunol, 2018. 200(8): p. 2915-
2926. 
122. Jiang, X., et al., Skin infection generates non-migratory memory CD8+ T(RM) cells 
providing global skin immunity. Nature, 2012. 483(7388): p. 227-31. 
123. Gilchuk, P., et al., A Distinct Lung-Interstitium-Resident Memory CD8(+) T Cell Subset 
Confers Enhanced Protection to Lower Respiratory Tract Infection. Cell Rep, 2016. 
16(7): p. 1800-9. 
124. Steinbach, K., et al., Brain-resident memory T cells represent an autonomous cytotoxic 
barrier to viral infection. J Exp Med, 2016. 213(8): p. 1571-87. 
125. Ariotti, S., et al., T cell memory. Skin-resident memory CD8(+) T cells trigger a state of 
tissue-wide pathogen alert. Science, 2014. 346(6205): p. 101-5. 
126. Ariotti, S., et al., Tissue-resident memory CD8+ T cells continuously patrol skin epithelia 
to quickly recognize local antigen. Proc Natl Acad Sci U S A, 2012. 109(48): p. 19739-
44. 
127. Zaid, A., et al., Persistence of skin-resident memory T cells within an epidermal niche. 
Proceedings of the National Academy of Sciences, 2014. 111(14): p. 5307-5312. 
128. Dijkgraaf, F.E., et al., Tissue patrol by resident memory CD8(+) T cells in human skin. 
Nat Immunol, 2019. 20(6): p. 756-764. 
129. Park, S.L., et al., Local proliferation maintains a stable pool of tissue-resident memory T 
cells after antiviral recall responses. Nat Immunol, 2018. 19(2): p. 183-191. 
130. Beura, L.K., et al., Intravital mucosal imaging of CD8(+) resident memory T cells shows 
tissue-autonomous recall responses that amplify secondary memory. Nat Immunol, 2018. 
19(2): p. 173-182. 
139 
 
131. Thompson, E.A., et al., Interstitial Migration of CD8alphabeta T Cells in the Small 
Intestine Is Dynamic and Is Dictated by Environmental Cues. Cell Rep, 2019. 26(11): p. 
2859-2867.e4. 
132. Fonseca, R., et al., Developmental plasticity allows outside-in immune responses by 
resident memory T cells. Nat Immunol, 2020. 21(4): p. 412-421. 
133. Klicznik, M.M., et al., Human CD4<sup>+</sup>CD103<sup>+</sup> cutaneous 
resident memory T cells are found in the circulation of healthy individuals. Science 
Immunology, 2019. 4(37): p. eaav8995. 
134. Fernandez-Ruiz, D., et al., Liver-Resident Memory CD8(+) T Cells Form a Front-Line 
Defense against Malaria Liver-Stage Infection. Immunity, 2016. 45(4): p. 889-902. 
135. Casey, K.A., et al., Antigen-independent differentiation and maintenance of effector-like 
resident memory T cells in tissues. J Immunol, 2012. 188(10): p. 4866-75. 
136. Wakim, L.M., A. Woodward-Davis, and M.J. Bevan, Memory T cells persisting within 
the brain after local infection show functional adaptations to their tissue of residence. 
Proc Natl Acad Sci U S A, 2010. 107(42): p. 17872-9. 
137. Smolders, J., et al., Tissue-resident memory T cells populate the human brain. Nat 
Commun, 2018. 9(1): p. 4593. 
138. Hombrink, P., et al., Programs for the persistence, vigilance and control of human 
CD8(+) lung-resident memory T cells. Nat Immunol, 2016. 17(12): p. 1467-1478. 
139. Piet, B., et al., CD8(+) T cells with an intraepithelial phenotype upregulate cytotoxic 
function upon influenza infection in human lung. J Clin Invest, 2011. 121(6): p. 2254-63. 
140. Seidel, J.A., et al., Skin resident memory CD8(+) T cells are phenotypically and 
functionally distinct from circulating populations and lack immediate cytotoxic function. 
Clin Exp Immunol, 2018. 194(1): p. 79-92. 
141. Mackay, L.K., et al., The developmental pathway for CD103(+)CD8+ tissue-resident 
memory T cells of skin. Nat Immunol, 2013. 14(12): p. 1294-301. 
142. Ichikawa, T., et al., CD103(hi) Treg cells constrain lung fibrosis induced by CD103(lo) 
tissue-resident pathogenic CD4 T cells. Nat Immunol, 2019. 20(11): p. 1469-1480. 
143. Oja, A.E., et al., Trigger-happy resident memory CD4(+) T cells inhabit the human 
lungs. Mucosal Immunol, 2018. 11(3): p. 654-667. 
144. Schenkel, J.M., et al., T cell memory. Resident memory CD8 T cells trigger protective 
innate and adaptive immune responses. Science, 2014. 346(6205): p. 98-101. 
145. Khan, T.N., et al., Local antigen in nonlymphoid tissue promotes resident memory CD8+ 
T cell formation during viral infection. J Exp Med, 2016. 213(6): p. 951-66. 
146. Cheuk, S., et al., CD49a Expression Defines Tissue-Resident CD8(+) T Cells Poised for 
Cytotoxic Function in Human Skin. Immunity, 2017. 46(2): p. 287-300. 
147. Schenkel, J.M., et al., Sensing and alarm function of resident memory CD8(+) T cells. 
Nat Immunol, 2013. 14(5): p. 509-13. 
148. Cuburu, N., et al., Topical herpes simplex virus 2 (HSV-2) vaccination with human 
papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident 
memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 
challenge. J Virol, 2015. 89(1): p. 83-96. 
149. Cuburu, N., et al., Intravaginal immunization with HPV vectors induces tissue-resident 
CD8+ T cell responses. J Clin Invest, 2012. 122(12): p. 4606-20. 
150. Hobbs, S.J. and J.C. Nolz, Targeted Expansion of Tissue-Resident CD8(+) T Cells to 
Boost Cellular Immunity in the Skin. Cell Rep, 2019. 29(10): p. 2990-2997.e2. 
140 
 
151. Davies, B., et al., Cutting Edge: Tissue-Resident Memory T Cells Generated by Multiple 
Immunizations or Localized Deposition Provide Enhanced Immunity. J Immunol, 2017. 
198(6): p. 2233-2237. 
152. Suarez-Ramirez, J.E., et al., Immunity to Respiratory Infection Is Reinforced Through 
Early Proliferation of Lymphoid TRM Cells and Prompt Arrival of Effector CD8 T Cells 
in the Lungs. Front Immunol, 2019. 10: p. 1370. 
153. Netea, M.G., et al., Defining trained immunity and its role in health and disease. Nature 
Reviews Immunology, 2020. 
154. Quintin, J., et al., Candida albicans infection affords protection against reinfection via 
functional reprogramming of monocytes. Cell Host Microbe, 2012. 12(2): p. 223-32. 
155. Yao, Y., et al., Induction of Autonomous Memory Alveolar Macrophages Requires T Cell 
Help and Is Critical to Trained Immunity. Cell, 2018. 175(6): p. 1634-1650.e17. 
156. Benn, C.S., et al., A small jab - a big effect: nonspecific immunomodulation by vaccines. 
Trends Immunol, 2013. 34(9): p. 431-9. 
157. Bull, N.C., et al., Enhanced protection conferred by mucosal BCG vaccination associates 
with presence of antigen-specific lung tissue-resident PD-1(+) KLRG1(-) CD4(+) T cells. 
Mucosal Immunol, 2019. 12(2): p. 555-564. 
158. Smale, S.T., A. Tarakhovsky, and G. Natoli, Chromatin contributions to the regulation of 
innate immunity. Annu Rev Immunol, 2014. 32: p. 489-511. 
159. Donohoe, D.R. and S.J. Bultman, Metaboloepigenetics: interrelationships between 
energy metabolism and epigenetic control of gene expression. J Cell Physiol, 2012. 
227(9): p. 3169-77. 
160. Cheng, S.-C., et al., mTOR- and HIF-1α–mediated aerobic glycolysis as metabolic basis 
for trained immunity. Science, 2014. 345(6204): p. 1250684. 
161. Saeed, S., et al., Epigenetic programming of monocyte-to-macrophage differentiation and 
trained innate immunity. Science, 2014. 345(6204): p. 1251086. 
162. Walsh, K.B., et al., Quelling the storm: utilization of sphingosine-1-phosphate receptor 
signaling to ameliorate influenza virus-induced cytokine storm. Immunol Res, 2011. 
51(1): p. 15-25. 
163. Subramanian, A., et al., Gene set enrichment analysis: A knowledge-based approach for 
interpreting genome-wide expression profiles. Proceedings of the National Academy of 
Sciences, 2005. 102(43): p. 15545-15550. 
164. Mootha, V.K., et al., PGC-1α-responsive genes involved in oxidative phosphorylation are 
coordinately downregulated in human diabetes. Nature Genetics, 2003. 34(3): p. 267-
273. 
165. Paules, C.I., et al., Chasing Seasonal Influenza - The Need for a Universal Influenza 
Vaccine. N Engl J Med, 2018. 378(1): p. 7-9. 
166. Liang, S., et al., Heterosubtypic immunity to influenza type A virus in mice. Effector 
mechanisms and their longevity. J Immunol, 1994. 152(4): p. 1653-61. 
167. Richards, K.A., et al., Cutting edge: CD4 T cells generated from encounter with seasonal 
influenza viruses and vaccines have broad protein specificity and can directly recognize 
naturally generated epitopes derived from the live pandemic H1N1 virus. J Immunol, 
2010. 185(9): p. 4998-5002. 
168. Koutsakos, M., et al., Human CD8(+) T cell cross-reactivity across influenza A, B and C 
viruses. Nat Immunol, 2019. 20(5): p. 613-625. 
141 
 
169. Pizzolla, A., et al., Influenza-specific lung-resident memory T cells are proliferative and 
polyfunctional and maintain diverse TCR profiles. J Clin Invest, 2018. 128(2): p. 721-
733. 
170. Marshall, D.R., et al., Measuring the diaspora for virus-specific CD8+ T cells. Proc Natl 
Acad Sci U S A, 2001. 98(11): p. 6313-8. 
171. Schenkel, J.M. and D. Masopust, Tissue-resident memory T cells. Immunity, 2014. 41(6): 
p. 886-97. 
172. Szabo, P.A., M. Miron, and D.L. Farber, Location, location, location: Tissue resident 
memory T cells in mice and humans. Sci Immunol, 2019. 4(34). 
173. Wu, T., et al., Lung-resident memory CD8 T cells (TRM) are indispensable for optimal 
cross-protection against pulmonary virus infection. J Leukoc Biol, 2014. 95(2): p. 215-
24. 
174. Zens, K.D., J.-K. Chen, and D.L. Farber, Vaccine-Generated Lung Tissue-Resident 
Memory T cells Provide Heterosubtypic Protection to Influenza Infection. J. Clin. Invest. 
Insight, 2016. 1 (10): p. e85832. 
175. Teijaro, J.R., et al., Memory CD4 T cells direct protective responses to influenza virus in 
the lungs through helper-independent mechanisms. J Virol, 2010. 84(18): p. 9217-26. 
176. Kitamura, D., et al., A B cell-deficient mouse by targeted disruption of the membrane 
exon of the immunoglobulin mu chain gene. Nature, 1991. 350(6317): p. 423-6. 
177. Cunningham, N.R., et al., Immature CD4+CD8+ thymocytes and mature T cells regulate 
Nur77 distinctly in response to TCR stimulation. J Immunol, 2006. 177(10): p. 6660-6. 
178. Ashouri, J.F. and A. Weiss, Endogenous Nur77 Is a Specific Indicator of Antigen 
Receptor Signaling in Human T and B Cells. J Immunol, 2017. 198(2): p. 657-668. 
179. Helft, J., et al., GM-CSF Mouse Bone Marrow Cultures Comprise a Heterogeneous 
Population of CD11c(+)MHCII(+) Macrophages and Dendritic Cells. Immunity, 2015. 
42(6): p. 1197-211. 
180. Meredith, M.M., et al., Expression of the zinc finger transcription factor zDC (Zbtb46, 
Btbd4) defines the classical dendritic cell lineage. J Exp Med, 2012. 209(6): p. 1153-65. 
181. Satpathy, A.T., et al., Zbtb46 expression distinguishes classical dendritic cells and their 
committed progenitors from other immune lineages. J Exp Med, 2012. 209(6): p. 1135-
52. 
182. Zens, K.D., et al., Reduced generation of lung tissue-resident memory T cells during 
infancy. J Exp Med, 2017. 214(10): p. 2915-2932. 
183. McKinstry, K.K., et al., Memory CD4+ T cells protect against influenza through multiple 
synergizing mechanisms. J Clin Invest, 2012. 122(8): p. 2847-56. 
184. Nayak, J.L., S. Alam, and A.J. Sant, Cutting edge: Heterosubtypic influenza infection 
antagonizes elicitation of immunological reactivity to hemagglutinin. J Immunol, 2013. 
191(3): p. 1001-5. 
185. Francis, T., On the Doctrine of Original Antigenic Sin. Proceedings of the American 
Philosophical Society, 1960. 104(6): p. 572-578. 
186. Kim, J.H., et al., Original antigenic sin responses to influenza viruses. J Immunol, 2009. 
183(5): p. 3294-301. 
187. Zhang, A., et al., Original Antigenic Sin: How First Exposure Shapes Lifelong Anti–




188. Netea, M.G., et al., Trained immunity: A program of innate immune memory in health 
and disease. Science, 2016. 352(6284): p. aaf1098. 
189. Mitroulis, I., et al., Modulation of Myelopoiesis Progenitors Is an Integral Component of 
Trained Immunity. Cell, 2018. 172(1-2): p. 147-161.e12. 
190. Beauchamp, N.M., R.Y. Busick, and M.A. Alexander-Miller, Functional Divergence 
among CD103<sup>+</sup> Dendritic Cell Subpopulations following Pulmonary 
Poxvirus Infection. Journal of Virology, 2010. 84(19): p. 10191-10199. 
191. Kedl, R.M., et al., Migratory dendritic cells acquire and present lymphatic endothelial 
cell-archived antigens during lymph node contraction. Nat Commun, 2017. 8(1): p. 2034. 
192. Hor, J.L., et al., Spatiotemporally Distinct Interactions with Dendritic Cell Subsets 
Facilitates CD4+ and CD8+ T Cell Activation to Localized Viral Infection. Immunity, 
2015. 43(3): p. 554-65. 
193. Wilk, M.M., et al., Lung CD4 Tissue-Resident Memory T Cells Mediate Adaptive 
Immunity Induced by Previous Infection of Mice with Bordetella pertussis. J Immunol, 
2017. 199(1): p. 233-243. 
194. Sakai, S., et al., Cutting edge: control of Mycobacterium tuberculosis infection by a 
subset of lung parenchyma-homing CD4 T cells. J Immunol, 2014. 192(7): p. 2965-9. 
195. Morabito, K.M., et al., Intranasal administration of RSV antigen-expressing MCMV 
elicits robust tissue-resident effector and effector memory CD8+ T cells in the lung. 
Mucosal Immunol, 2017. 10(2): p. 545-554. 
196. Teijaro, J.R., Cytokine storms in infectious diseases. Seminars in immunopathology, 
2017. 39(5): p. 501-503. 
197. Kobasa, D., et al., Aberrant innate immune response in lethal infection of macaques with 
the 1918 influenza virus. Nature, 2007. 445(7125): p. 319-23. 
198. de Jong, M.D., et al., Fatal outcome of human influenza A (H5N1) is associated with high 
viral load and hypercytokinemia. Nat Med, 2006. 12(10): p. 1203-7. 
199. Thiel, V. and F. Weber, Interferon and cytokine responses to SARS-coronavirus infection. 
Cytokine Growth Factor Rev, 2008. 19(2): p. 121-32. 
200. Teijaro, John R., et al., Endothelial Cells Are Central Orchestrators of Cytokine 
Amplification during Influenza Virus Infection. Cell, 2011. 146(6): p. 980-991. 
201. Hogner, K., et al., Macrophage-expressed IFN-beta contributes to apoptotic alveolar 
epithelial cell injury in severe influenza virus pneumonia. PLoS Pathog, 2013. 9(2): p. 
e1003188. 
202. Perrone, L.A., et al., H5N1 and 1918 Pandemic Influenza Virus Infection Results in Early 
and Excessive Infiltration of Macrophages and Neutrophils in the Lungs of Mice. PLOS 
Pathogens, 2008. 4(8): p. e1000115. 
203. Moskophidis, D. and D. Kioussis, Contribution of virus-specific CD8+ cytotoxic T cells 
to virus clearance or pathologic manifestations of influenza virus infection in a T cell 
receptor transgenic mouse model. J Exp Med, 1998. 188(2): p. 223-32. 
204. Peper, R.L. and H. Van Campen, Tumor necrosis factor as a mediator of inflammation in 
influenza A viral pneumonia. Microb Pathog, 1995. 19(3): p. 175-83. 
205. Branchett, W.J. and C.M. Lloyd, Regulatory cytokine function in the respiratory tract. 
Mucosal Immunology, 2019. 12(3): p. 589-600. 
206. Brooks, D.G., et al., Interleukin-10 determines viral clearance or persistence in vivo. Nat 
Med, 2006. 12(11): p. 1301-9. 
143 
 
207. Loebbermann, J., et al., IL-10 regulates viral lung immunopathology during acute 
respiratory syncytial virus infection in mice. PLoS One, 2012. 7(2): p. e32371. 
208. Sun, J., et al., Autocrine regulation of pulmonary inflammation by effector T-cell derived 
IL-10 during infection with respiratory syncytial virus. PLoS Pathog, 2011. 7(8): p. 
e1002173. 
209. Zaslavsky, E., et al., Antiviral Response Dictated by Choreographed Cascade of 
Transcription Factors. The Journal of Immunology, 2010. 184(6): p. 2908-2917. 
210. Napolitani, G., et al., Selected Toll-like receptor agonist combinations synergistically 
trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol, 2005. 6(8): 
p. 769-76. 
211. O'Dwyer, D.N., R.P. Dickson, and B.B. Moore, The Lung Microbiome, Immunity, and 
the Pathogenesis of Chronic Lung Disease. Journal of immunology (Baltimore, Md. : 
1950), 2016. 196(12): p. 4839-4847. 
212. Gerosa, F., et al., CD4(+) T cell clones producing both interferon-gamma and 
interleukin-10 predominate in bronchoalveolar lavages of active pulmonary tuberculosis 





Appendix A: Accepted Abstracts 
Oral Presentation: Lung Tissue Resident Memory T cells coordinate effector cell tissue 
infiltration during influenza infection 
Paik DH, Farber DL 
 
American Association of Immunologists (AAI) 
Immunology 2018. Austin, TX 
Travel Award Recipient 
 
Abstract: 
Influenza is a leading cause of hospitalizations and deaths worldwide, and annual 
vaccinations are required to generate protective antibodies against a narrow range of strains.  
Lung tissue resident memory (TRM) T cells are a non-circulating memory subset that are 
generated after infection or live vaccination, and these TRM confer broad cross-strain protection.  
However, the mechanisms by which they mediate their protective response are not defined.  We 
investigated the tissue specific events during an active murine influenza response, including 
TRM-mediated protection and effector T cell trafficking.  To specifically determine the role of 
TRM, we treated mice with the drug Fingolimod (FTY720), which sequesters circulating 
lymphocytes into secondary lymphoid organs, enriching the lung for tissue resident memory 
cells.  During FTY720 treatment, we found that TRM cells confer protection against influenza 
virus very early in the disease course.  Later in the disease course by Day 5, TRM also 
coordinate the recruitment of influenza-specific effector T cells into the lung resident niche and 
mediate in situ proliferation as measured by BrdU incorporation.  Total lung RNA sequencing 
during active infection and FTY720 treatment reveal candidate TRM-associated chemokine 
pathways for tissue lymphocyte trafficking. These findings indicate that TRM uniquely influence 
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Paik DH, Farber DL.  Influenza infection imprints local lymphoid sites to promote lung resident 
heterosubtypic immunity.  Journal of Experimental Medicine.  In review. 
 
Influenza infection generates tissue-resident memory T cells (TRM) that are maintained 
in the lung and can mediate protective immunity to heterologous influenza strains, though the 
precise mechanisms of local T cell-mediated protection are not well understood.  In a murine 
heterosubtypic influenza challenge model, we demonstrate that protective lung T cell responses 
are independent of B cell responses, and derive from in situ activation of tissue resident memory 
T cell (TRM) and the enhanced generation of effector T cells from the local lung draining 
mediastinal lymph nodes (medLN).  Primary infection fortified the medLN with an increased 
number of conventional dendritic cells (cDC) that mediate enhanced priming of T cells, 
including those specific for newly encountered epitopes; cDC depletion during the recall 
response diminished medLN T cell generation and heterosubtypic immunity. Our study shows 
that during a protective recall response, cDC in a fortified LN environment enhance the breadth, 




Turner DL, Goldklang M, Cvetkovski F, Paik D, Trischler J, Barahona J, Cao M, Dave R, Tanna 
N, D'Armiento JM, Farber DL (2018). Biased Generation and In Situ Activation of Lung Tissue-
Resident Memory CD4 T Cells in the Pathogenesis of Allergic Asthma. J Immunol. doi: 
10.4049/jimmunol.1700257.  
 
Asthma is a chronic inflammatory disease mediated by allergen-specific CD4 T cells that 
promote lung inflammation through recruitment of cellular effectors into the lung. A subset of lung 
T cells can persist as tissue-resident memory T cells (TRMs) following infection and allergen 
induction, although the generation and role of TRM in asthma persistence and pathogenesis remain 
unclear. In this study, we used a mouse model of chronic exposure to intranasal house dust mite 
(HDM) extract to dissect how lung TRMs are generated and function in the persistence and 
pathogenesis of allergic airway disease. We demonstrate that both CD4+ and CD8+ T cells 
infiltrate into the lung tissue during acute HDM exposure; however, only CD4+ TRMs, and not 
CD8+ TRMs, persist long term following cessation of HDM administration. Lung CD4+ TRMs 
are localized around airways and are rapidly reactivated upon allergen re-exposure accompanied 
by the rapid induction of airway hyperresponsiveness independent of circulating T cells. Lung 
CD4+ TRM activation to HDM challenge is also accompanied by increased recruitment and 
activation of dendritic cells in the lungs. Our results indicate that lung CD4+ TRMs can perpetuate 
allergen-specific sensitization and direct early inflammatory signals that promote rapid lung 
pathology, suggesting that targeting lung CD4+ TRMs could have therapeutic benefit in alleviating 
recurrent asthma episodes. 
 
